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A B S T R A C T
Background
It is generally assumed by practitioners and guideline authors that combined modalities (methods of treatment) are more effective than
single modalities in preventing venous thromboembolism (VTE), defined as deep vein thrombosis (DVT) or pulmonary embolism
(PE), or both. This is an update of the review first published in 2008.
Objectives
The aim of this review was to assess the efficacy of combined intermittent pneumatic leg compression (IPC) and pharmacological
prophylaxis versus single modalities in preventing venous thromboembolism.
Search methods
For this update the Cochrane Vascular Information Specialist (CIS) searched the Specialised Register (May 2016). In addition the CIS
searched the Cochrane Register of Studies (CENTRAL (2016, Issue 4)). Clinical trials databases were searched for details of ongoing
or unpublished studies.
Selection criteria
Randomized controlled trials (RCTs) or controlled clinical trials (CCTs) of combined IPC and pharmacological interventions used to
prevent VTE.
Data collection and analysis
We independently selected trials and extracted data. Disagreements were resolved by discussion. We performed fixed-effect model meta-
analyses with odds ratios (ORs) and 95% confidence intervals (CIs). We used a random-effects model when there was heterogeneity.
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Main results
We included a total of 22 trials (9137 participants) of which 15 were randomized trials (7762 participants). The overall risk of bias
was mostly unclear or high due to selection and performance bias. We used GRADE to assess the quality of the evidence and this was
downgraded from high to moderate or very low due to the risk of bias, imprecision or indirectness.
The rate of PE in the studies comparing IPC alone with combined IPC and pharmacological prophylaxis was low, underpowering the
analyses. The incidence of symptomatic PEwas 0.79%with IPC, but rangedbetween0.1 to 1%with combined IPCandpharmacological
prophylaxis (OR 0.49, 95% CI 0.18 to 1.34; 12 studies, 3017 participants, moderate quality evidence). The incidence of DVT was
4.10% in the IPC group and 2.19% in the combined group showing a reduced incidence of DVT in favour of the combined group
(OR 0.52, 95% CI 0.33 to 0.82; 11 studies, 2934 participants, moderate quality evidence). The addition of an anticoagulant to IPC,
however, increased the risk of any bleeding compared to IPC alone; 0.66% (7/1053) in the IPC group and 4.0% (44/1102) in the
combined group (OR 5.04, 95% CI 2.36 to 10.77; 7 studies, 2155 participants, moderate quality evidence). Major bleeding followed
a similar pattern; 0.1% (1/1053) in the IPC group to 1.5% (17/1102) in the combined group (OR 6.81, 95% CI 1.99 to 23.28; 7
studies, 2155 participants, moderate quality evidence).
We detected no difference between the type of surgery subgroups such as orthopedic and non-orthopedic participants forDVT incidence
(P = 0.16). Tests for differences between type of surgery subgroups were not possible for PE incidence.
Compared with pharmacological prophylaxis alone, the use of combined IPC and pharmacological prophylaxis modalities reduced the
incidence of symptomatic PE from 2.92% to 1.20% (OR 0.39, 95% CI 0.23 to 0.64; 10 studies, 3544 participants, moderate quality
evidence). The incidence of DVT was 6.2% in the pharmacological prophylaxis group and 2.9% in the combined group showing
no difference between the combined and pharmacological prophylaxis groups (OR 0.42, 95% CI 0.18 to 1.03; 11 studies, 2866
participants, moderate quality evidence). Increased bleeding side effects were not observed for IPC when it was added to anticoagulation
(bleeding: OR 0.80, 95% CI 0.30 to 2.14, very low quality evidence; major bleeding: OR 1.21, 95% CI 0.35 to 4.18, very low quality
evidence, 3 studies, 244 participants).
No difference was detected between the type of surgery subgroups for PE incidence (P = 0.68) or for DVT incidence (P = 0.10).
Authors’ conclusions
Moderate quality evidence suggests that combining IPC and pharmacological prophylaxis, compared with IPC or pharmacological
prophylaxis alone, decreases the incidence of DVT when compared to compression, and incidence of PE when compared to antico-
agulation. Moderate quality evidence suggests that there is no difference between combined and single modalities in the incidence of
PE when compared with compression alone and DVT when compared with anticoagulation alone. The quality of evidence for PE or
DVT was downgraded to moderate due to imprecision or risk of bias in study methodology, highlighting the need for further research.
Moderate quality evidence suggests the addition of pharmacological prophylaxis to IPC, increased the risk of bleeding compared to
IPC alone, a side effect not observed for IPC when added to pharmacological prophylaxis (very low quality evidence), as expected for a
physical method of thromboprophylaxis. The quality of evidence for bleeding was downgraded to moderate due to indirectness or very
low due to risk of bias in study methodology, indirectness and imprecision highlighting the need for further research. Nevertheless,
the results of the current review agree with current guideline recommendations, which support the use of combined modalities in
hospitalised patients (limited to those with trauma or undergoing surgery) at risk of developing VTE. More studies on the role of
combined modalities in VTE prevention are needed.
P L A I N L A N G U A G E S U M M A R Y
Combined intermittent pneumatic leg compression and medication for the prevention of deep vein thrombosis and pulmonary
embolism
Background
Deep vein thrombosis (DVT) and pulmonary embolism (PE) are collectively known as venous thromboembolism (VTE), and occur
when a blood clot develops inside the leg veins (DVT) and travels to the lungs (PE). They are possible complications of hospitalisation
resulting from surgery or trauma. These complications extend hospital stay and are associated with long-term disability and death.
Patients undergoing total hip or knee replacement surgery or surgery for colorectal cancer are at high risk of venous thromboembolism.
Sluggish venous blood flow, increased blood clotting and blood vessel wall injury are contributing factors. Treating more than one of
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these causes may improve prevention. Mechanical intermittent pneumatic leg compression (IPC) reduces sluggish blood flow (venous
stasis) while medications such as aspirin and anticoagulants (low molecular weight heparin) reduce blood clotting. These medications
are known as pharmacological prophylaxis (drugs used to prevent blood clots). However, these medications can also increase the risk
of bleeding. This review is an update of a review first published in 2008.
Study characteristics and key results
We identified 22 trials with a total of 9137 participants to include in this review (current until May 2016). Themean age of participants,
where reported, was 65.2 years. Most participants had either a high-risk procedure or condition. The predisposing conditions were
orthopedic surgery in 12 studies and urology, cardiothoracic, neurosurgery, trauma, general surgery, gynaecology or other types of
participants in the remaining studies.
Compared to IPC alone, IPC plus medication did not show differences in the incidence (rate of new cases) of PE (12 studies with a
total of 3017 participants). The incidence of DVT was reduced for IPC combined with medication when compared with IPC alone (11
studies with a total of 2934 participants). The addition of a medication to IPC, however, increased the risk for any bleeding compared
to IPC alone, from 0.66% to 4.0%. Major bleeding followed a similar pattern, with an increase from 0.1% to 1.5%.Further analysis
looking at different subgroups of participants (orthopedic and non-orthopedic participants) did not show any overall difference in
DVT while it was not possible to assess differences between subgroups for PE.
Comparedwithmedication alone, combined IPC andmedication reduced the incidence of PE (10 studies with 3544 participants). DVT
incidence was not different between the medication and the combined IPC and medication group (11 studies with 2866 participants).
No differences were observed in rates of bleeding (three studies with 244 participants). Further analysis looking at different subgroups
of participants did not show any overall difference in incidence of PE and DVT between orthopedic and non-orthopedic participants.
Quality of the evidence
The findings of this review show moderate quality evidence and agree with current guideline recommendations supporting the use of
combined IPC and pharmacological prophylaxis, compared with IPC or pharmacological prophylaxis alone, to reduce the incidence
of DVT and PE in hospitalized patients. Moderate quality evidence suggests the addition of pharmacological prophylaxis to IPC,
increased the risk of bleeding compared to IPC alone, a side effect not observed for IPC when added to pharmacological prophylaxis
(very low quality evidence), as expected for a physical method for preventing blood clots. The quality of the evidence was downgraded
from high to moderate or very low for risk of bias and imprecision and indirectness between the studies.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Does combined intermittent pneumatic compression (IPC) plus pharmacological prophylaxis increase prevention of venous thromboembolism compared with IPC alone?
Patient or population: pat ients undergoing surgery or at risk of developing VTE because of other reasons (e.g. trauma)
Settings: hospital (surgery, trauma or ICU stay)
Intervention: combined IPC plus pharmacological prophylaxis
Comparison: IPC alone
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Single modalities Combined modalities
Incidence of PEa 8 per 1000 4 per 1000 (1 to 10) OR 0.49 (0.18 to 1.34) 3017 (12) ⊕⊕⊕©
moderate1
Incidence of DVT b 41 per 1000 22 per 1000 (14 to 34) OR 0.52 (0.33 to 0.82) 2934 (11) ⊕⊕⊕©
moderate2
Incidence of bleedingc 7 per 1000 33 per 1000 (16 to 67) OR 5.04 (2.36 to 10.77) 2155 (7) ⊕⊕⊕©
moderate3
Incidence of major
bleedingd
1 per 1000 6 per 1000 (2 to 22) OR 6.81 (1.99 to 23.28) 2155 (7) ⊕⊕⊕©
moderate3
* The basis for the assumed risk was the average risk in the single modalit ies group (i.e. the number of part icipants with events divided by total number of part icipants of the
single modalit ies group included in the meta-analysis). The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the comparison group and
the relative effect of the intervent ion (and its 95% CI)
CI: conf idence interval;DVT: deep vein thrombosis;IPC: interm it tent pneumatic compression; OR: odds rat io; PE: pulmonary embolism; VTE: venous thromboembolism
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.4
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a PE assessed by pulmonary angiography or scint igraphy, computed tomography (CT), angiography, or autopsy
b DVT assessed by ascending venography, I-125 f ibrinogen uptake test, and ultrasound scanning
c any type of bleeding as described by the study authors
d major bleeding as def ined by the study authors, but usually located at the surgical site or in a crit ical organ or site, requiring
intervent ion or transfusion of at least units of blood, or leading to death
1 Downgraded by one level due to imprecision likely due to a type II error (few events and 4/ 12 studies contribut ing to ef fect
est imate)
2 Downgraded by one level, due to risk of attrit ion bias, af fect ing ef fect est imate as shown by sensit ivity analysis
3 Downgraded by one level due to indirectness (report ing of bleeding outcomes (major and minor bleeding) was not uniform
across the studies, with some studies report ing on blood loss during the procedures or through the drains or providing rates
for postoperat ive bleeding. Def init ions used were also not uniform)
Bleeding events may be af fected by bias due to blinding. Only two out of seven studies are double blind. These are also the
two largest studies in the analysis. When pooled they show a sim ilar direct ion of ef fect (increased bleeding for combined
modalit ies) as the overall ef fect for the seven studies in this comparison indicat ing that any potent ial risk of risk of
performance or detect ion bias does not af fect the results therefore not downgraded for risk of bias
Wide conf idence interval but upper and lower lim its of corresponding risk and 95% conf idence interval of ef fect both show
the same message i.e. an increased risk of bleeding for combined modalit ies therefore not downgraded for imprecision
5
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B A C K G R O U N D
Description of the condition
Deep vein thrombosis (DVT), i.e. the development of thrombi
inside the deep veins of the legs (in most instances), is a poten-
tially fatal disease as it can be complicated by pulmonary embolism
(PE), resulting from the movement of thrombi from the leg veins
to the pulmonary artery or its branches. The incidence of venous
thromboembolism (VTE), DVT, PE or both, is still high despite
the use of contemporary prophylactic measures. VTE risk is in-
creased by the presence of certain risk factors, including, age, ma-
lignancy, immobilisation and the type of surgery. High-risk pa-
tients include those undergoing total hip or knee replacement,
or surgery for colorectal cancer (McLeod 2001). Experts in the
field have indicated that this and similar observations are the result
of failed and also omitted prophylaxis (Goldhaber 2001; Piazza
2007). The most recent guidelines recommend combined phar-
macological andmechanical prophylaxis in high-risk groups, in an
effort to maximize thromboprophylaxis (Gould 2012; Nicolaides
2013). It is likely that mechanical methods increase the efficacy of
thromboprophylaxis and reduce death and morbidity rates with-
out increasing bleeding risk.
Description of the intervention
Intermittent pneumatic leg compression (IPC) involves wrapping
the legs with inflatable sleeves, using commercially available de-
vices. As a result of sleeve inflation, external pressure is exerted on
the legs and its veins, resulting in an increase in blood flow and this
reduction of blood stasis decreases the incidence of VTE. Phar-
macological prophylaxis on the other hand is achieved by mostly
small doses of anticoagulants given orally or subcutaneously; these
also significantly reduce the incidence of VTE. Combined IPC
and pharmacological prophylaxis in the form of dual modalities
concurrently used for prevention of VTEmay improve the efficacy
of each method used alone.
How the intervention might work
Mechanical methods reduce VTE mainly by reducing venous sta-
sis, while anticoagulants inhibit elements of the thrombosis cas-
cade. Because single prophylactic modalities reduce but not com-
pletely eliminate VTE, combined modalities are expected to re-
duce further the frequency of VTEbecause of their differentmech-
anisms of action.
Why it is important to do this review
Venous thromboembolism is the single most common, pre-
ventable cause of postoperative death. Better use of preventive re-
sources is expected to reduce VTE events and mortality. Use of
combined modalities is suggested by current guidelines in high
risk patients, however the evidence supporting these recommen-
dations requires better attention (Gould 2012; Nicolaides 2013).
We performed this review to assess the breadth and strength of
the best available evidence by pooling data from multiple studies
to overcome limitations of small and underpowered studies. This
review is an update of a review first published in 2008.
O B J E C T I V E S
The aim of this review was to assess the efficacy of combined in-
termittent pneumatic leg compression (IPC) and pharmacological
prophylaxis versus single modalities in preventing venous throm-
boembolism.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomized controlled trials (RCTs) and controlled
clinical trials (CCTs).
Types of participants
We included any type of hospitalized patient requiring prevention
of venous thromboembolism (VTE) or at risk of developing VTE.
We included patients undergoing surgery and trauma and ICU
patients.
Types of interventions
We included studies which assessed the combined use of inter-
mittent pneumatic leg compression (IPC) (including foot pumps
and devices inflating calf sleeves) and pharmacological prophylaxis
(including unfractionated heparin and low molecular weight hep-
arin) compared with IPC or pharmacological prophylaxis alone.
We excluded studies that used IPC for a short period of time (that
is intraoperatively).
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Types of outcome measures
Primary outcomes
Venous thromboembolism (symptomatic or asymptomatic) was
the main outcome measure, with data on DVT and PE extracted
as separate endpoints.
Outcomes were assessed by: ascending venography, I-125 fibrino-
gen uptake test and ultrasound scanning for DVT; and pulmonary
angiography or scintigraphy, computed tomography (CT), an-
giography and autopsy for PE.
Secondary outcomes
Bleeding was considered as a safety outcome and included all types
reported i.e. any type, major bleeding (as defined by the study
authors, but usually located at the surgical site or in a critical organ
or site, requiring intervention or transfusion of at least two units of
blood, or leading to death), and fatal bleeding reported separately.
Fatal PE was an additional outcome.
Search methods for identification of studies
Electronic searches
For this update the Cochrane Vascular Information Specialist
(CIS) searched the Specialised Register (May 2016). In addi-
tion the CIS searched the Cochrane Register of Studies (CRS)
www.metaxis.com/CRSWeb/Index.asp (CENTRAL (2016, Issue
4)). See Appendix 1 for details of the search strategy used to
search the CRS. The Specialised Register is maintained by the
CIS and is constructed from weekly electronic searches of MED-
LINE, EMBASE, CINAHL, AMED, and through handsearch-
ing relevant journals. The full list of the databases, journals and
conference proceedings which have been searched, as well as the
search strategies used are described in the Specialised Register sec-
tion of the Cochrane Vascular module in the Cochrane Library (
www.cochranelibrary.com).
The following trial databases were searched by theCIS (May 2016)
for details of ongoing and unpublished studies using the terms
pneumatic compression;
World Health Organization International Clinical Trials Registry
(apps.who.int/trialsearch/)
ClinicalTrials.gov (clinicaltrials.gov/)
ISRCTN Register (www.isrctn.com/)
Searching other resources
We searched the reference lists of relevant articles and also similar
systematic reviews and meta-analyses to identify additional trials.
Data collection and analysis
Selection of studies
Two review authors (SK and IN) independently selected studies
for inclusion on the basis of use of combined mechanical IPC and
pharmacological modalities. Any disagreements were resolved by
discussion.
Data extraction and management
SKK and two co-authors (GG and IN) independently extracted
the data. We used a data extraction form to record the type of
patient or surgical procedure, total number of participants in the
study (including those randomized, excluded and alsowithdrawn),
the interventions used, the number of participants who reached
an endpoint (DVT or PE) and the methodology used to establish
this. A third author (JC) arbitrated any disagreements.
Assessment of risk of bias in included studies
We assessed the methodological quality of all included studies
using Cochrane’s ’Risk of bias’ tool. . SKK and two co-authors
(GG and IN) independently performed the assessment according
to Higgins 2011. The following domains were assessed: selection
bias (random sequence generation, allocation concealment), per-
formance bias (blinding of participants and personnel), detection
bias (blinding of outcome assessment), attrition bias (incomplete
outcome data), reporting bias (selective reporting) and other bias.
We classified the domains as low risk, high risk, or unclear risk
according to Higgins 2011. Any disagreements were resolved after
discussion.
Measures of treatment effect
We performed separate analysis for the interventions of IPC ver-
sus combined modalities, and pharmacological prophylaxis versus
combined modalities for the outcomes of PE and DVT. We used
odds ratios (OR) and risk ratio (RR) with 95% confidence inter-
vals (CIs) for assessment of dichotomous outcomes of all trials and
RCTs only, respectively.
Unit of analysis issues
We excluded studies with non-standard designs, such as cross-over
trials and cluster-randomized trials. The individual patient was the
unit of analysis.
Dealing with missing data
In case of missing participants due to drop-out, we used intention-
to-treat analysis. Where necessary, we contacted study authors to
request that they provided any missing information.
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Assessment of heterogeneity
We assessed statistical heterogeneity with the I2 test. I2 levels ex-
ceeding 50% were considered as substantial heterogeneity to jus-
tify the use of random-effects analysis.
Assessment of reporting biases
We assessed publication bias with funnel plots when 10 or more
studies were included in a comparison and contributed to the
effect estimate; as described by Higgins 2011. Where the number
of studies in each comparison was not greater than 10 the plots
lack the power to distinguish chance from real asymmetry (Egger
1997).
Data synthesis
We used fixed-effect models for each meta-analysis to pool data,
unless there was evidence of heterogeneity in which case we used
a random-effects model to calculate the RR or ORs and 95% CIs
(see Assessment of heterogeneity)..
Subgroup analysis and investigation of heterogeneity
We performed subgroup analysis of the primary outcomes for
surgery type (e.g. orthopedic surgery, etc), type of DVT (symp-
tomatic) and type of IPC (foot IPC and other than foot IPC).
Sensitivity analysis
We performed sensitivity analysis of the primary outcomes by
excluding studies with a high-risk for bias, based on the ’Risk of
bias’ tool, and by excluding CCTs, in order to test the robustness
of the evidence. Where significant heterogeneity was present, we
performed sensitivity analysis to determine what effect this had on
the results.
Summary of findings
We created ’Summary of findings’ tables for the comparisons of
IPCplus pharmacological prophylaxis versus IPCalone (Summary
of findings for the main comparison) and IPC plus pharma-
cological prophylaxis versus pharmacological prophylaxis alone
(Summary of findings 2). We used GRADEpro GDT software (
GRADEpro GDT 2015) to present the main findings of the re-
view. We included the primary outcomes DVT and PE and inci-
dence of bleeding and major bleeding in the ’Summary of find-
ings’ tables.We calculated assumed control intervention risks from
the mean number of events in the control groups of the selected
studies for each outcome. The system developed by the Grading
of Recommendation, Assessment, Development and Evaluation
Working Group (GRADE working group) was used for grading
the quality of evidence as high, moderate, low and very low, based
on within-study risk of bias, directness of evidence, heterogeneity,
precision of effects estimates, and risk of publication bias (Atkins
2004).
R E S U L T S
Description of studies
Results of the search
See Figure 1.
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Figure 1. Study flow diagram.
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Included studies
For this update 11 additional studies were included (Cahan
2000; Dickinson 1998; Edwards 2008; Kurtoglu 2003; Sakai
2016; Siragusa 1994; Song 2014; Stannard 1996; Tsutsumi 2012;
Windisch 2011; Yokote 2011)making a total of 22 studies thatmet
the inclusion criteria, reporting outcomes on 9137 participants
(Bigg 1992; Borow 1983; Bradley 1993; Cahan 2000; Dickinson
1998; Edwards 2008; Eisele 2007; Kurtoglu 2003; Ramos 1996;
Sakai 2016; Sieber 1997; Silbersack 2004; Siragusa 1994; Song
2014; Stannard 1996; Tsutsumi 2012; Turpie 2007; Westrich
2005; Westrich 2006; Windisch 2011; Woolson 1991; Yokote
2011). Four publications had three arms (Borow 1983; Cahan
2000; Dickinson 1998; Stannard 1996), using IPC, pharmaco-
logical prophylaxis and both, respectively. Fifteen studies were
RCTs (Cahan 2000; Dickinson 1998; Edwards 2008; Eisele 2007;
Ramos 1996; Sakai 2016; Silbersack 2004; Siragusa 1994; Song
2014; Stannard 1996; Turpie 2007; Westrich 2006; Windisch
2011; Yokote 2011; Woolson 1991) that studied a total of 7762
participants. The remaining seven studies were CCTs, which
were classified according to the draft guidelines of the Cochrane
Non-Randomised Studies Methods Group (NRSMG). These in-
cluded three quasi-randomized CCTs (Bigg 1992; Bradley 1993;
Kurtoglu 2003) that studied a total of 222 participants, and
four CCTs with concurrent controls (Borow 1983; Sieber 1997;
Tsutsumi 2012; Westrich 2005) that involved a total of 1153 par-
ticipants.
The included studies evaluated orthopedic patients (n = 12)
(Bradley 1993; Edwards 2008; Eisele 2007; Sakai 2016; Silbersack
2004; Siragusa 1994; Stannard 1996; Westrich 2005; Westrich
2006; Windisch 2011; Woolson 1991; Yokote 2011); urology pa-
tients (n = 2) (Bigg 1992; Sieber 1997); cardiothoracic patients
(n = 1) (Ramos 1996); neurosurgery patients (n = 1) (Dickinson
1998); trauma patients (n = 1) (Kurtoglu 2003) or general surgery,
gynecology and other types of patients (n = 5) (Borow 1983;
Cahan 2000; Song 2014; Tsutsumi 2012; Turpie 2007). Patient
weighted mean age (in 17 studies that reported age, 5638 partic-
ipants) was 65.2 years (Bigg 1992; Bradley 1993; Cahan 2000;
Dickinson 1998; Edwards 2008; Ramos 1996; Sakai 2016; Sieber
1997; Silbersack 2004; Song 2014; Stannard 1996; Tsutsumi
2012; Westrich 2005; Westrich 2006; Windisch 2011; Woolson
1991; Yokote 2011).
Pharmacological prophylaxis included unfractionated heparin
(UFH) (Bigg 1992; Bradley 1993; Cahan 2000; Ramos 1996;
Sieber 1997; Siragusa 1994; Stannard 1996), lowmolecularweight
heparin (LMWH) (Dickinson 1998; Edwards 2008; Kurtoglu
2003; Silbersack 2004; Song 2014; Westrich 2006; Windisch
2011), fondaparinux (Eisele 2007; Tsutsumi 2012; Turpie 2007),
LMWHor fondaparinux (Yokote 2011), UFHorwarfarin (Borow
1983), warfarin or aspirin (Westrich 2005; Woolson 1991) and
edoxaban, a direct oral Factor Xa inhibitor (Sakai 2016).
IPC types included foot pumps (Bradley 1993; Sakai 2016;
Stannard 1996; Windisch 2011), and devices inflating calf sleeves
(Edwards 2008; Eisele 2007; Silbersack 2004; Westrich 2005;
Westrich 2006), or thigh-high sleeves (Bigg 1992; Borow 1983;
Cahan 2000; Dickinson 1998; Ramos 1996; Sieber 1997; Song
2014;Woolson 1991). The exact IPC typewas not reported in four
studies (Kurtoglu 2003; Siragusa 1994; Tsutsumi 2012; Yokote
2011), while in one multi centre study the investigators were al-
lowed to use the device type of their choice (Turpie 2007).
Four publications had three arms (Borow 1983; Cahan 2000;
Dickinson 1998; Stannard 1996), using IPC, pharmacological
prophylaxis and both, respectively. Of the remaining 18 publica-
tions, prophylactic methods in the control group included: IPC
in 11 studies, either without aspirin (Bigg 1992; Kurtoglu 2003;
Ramos 1996; Sieber 1997; Song 2014; Tsutsumi 2012; Turpie
2007; Woolson 1991; Yokote 2011) or with aspirin (Westrich
2005; Westrich 2006); and pharmacological prophylaxis in seven
studies (Bradley 1993; Edwards 2008; Eisele 2007; Sakai 2016;
Silbersack 2004; Siragusa 1994; Windisch 2011), with aspirin in
one of them (Silbersack 2004). The intervention group in all stud-
ies used combined modalities and aspirin was used only in two
studies (Stannard 1996; Woolson 1991).
Ultrasound was the main diagnostic modality to diagnose DVT
and was used by most studies (Borow 1983; Cahan 2000;
Dickinson 1998; Edwards 2008; Eisele 2007; Kurtoglu 2003;
Sakai 2016; Silbersack 2004; Siragusa 1994; Song 2014; Stannard
1996; Westrich 2005; Westrich 2006; Windisch 2011; Woolson
1991; Yokote 2011). PE, where reported, was diagnosed mainly
with scintigraphy scanning (Bigg 1992;Ramos 1996;Turpie 2007;
Woolson 1991), a pulmonary angiogram (Ramos 1996; Turpie
2007); or a CT pulmonary angiogram (Kurtoglu 2003; Sakai
2016; Silbersack 2004; Song 2014; Tsutsumi 2012; Turpie 2007;
Westrich 2006; Windisch 2011; Yokote 2011).
Two studies did not report on DVT rates (Bigg 1992; Ramos
1996), and four studies did not report on PE rates (Bradley 1993;
Dickinson 1998; Eisele 2007; Siragusa 1994).
Eleven studies reported on bleeding outcomes (Bigg 1992;
Dickinson 1998; Sakai 2016; Song 2014; Tsutsumi 2012; Turpie
2007; Westrich 2005; Westrich 2006; Windisch 2011; Woolson
1991; Yokote 2011). For many studies no specific bleeding defi-
nitions were provided (Bigg 1992; Dickinson 1998; Song 2014;
Westrich 2005; Westrich 2006; Windisch 2011; Woolson 1991).
For the remaining studies that did provide bleeding definitions,
the criteria were not uniform (Sakai 2016; Tsutsumi 2012; Turpie
2007; Yokote 2011).
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Excluded studies
For this update an additional nine studies were excluded (Gagner
2012; Kiudelis 2010; Kumaran 2008; Lieberman 1994; Mehta
2010; Patel 2010; Wan 2015; Westrich 1996; Whitworth 2011);
making a total of 21 excluded studies (Ailawadi 2001; Eskander
1997; Frim 1992; Gagner 2012; Gelfer 2006; Kamran 1998;
Kiudelis 2010; Kumaran 2008; Lieberman 1994; Macdonald
2003; Mehta 2010; Nathan 2006; Patel 2010; Roberts 1975;
Spinal cord injury investigators; Stannard 2006; Tsutsumi 2000;
Wan 2015; Westrich 1996; Whitworth 2011; Winemiller 1999).
Exclusions were due to: use of combined modalities was not con-
current or a different type of pharmacological prophylaxis was
given in the two study groups (n = 5) (Eskander 1997; Gelfer
2006;Macdonald 2003; Spinal cord injury investigators; Stannard
2006); IPC use was limited to intraoperative use (n = 2) (Kiudelis
2010; Roberts 1975); they were controlled before and after studies
(n = 3) (Frim 1992; Kamran 1998; Tsutsumi 2000); they were
retrospective case-control studies (n = 6) (Ailawadi 2001; Nathan
2006; Patel 2010; Wan 2015; Whitworth 2011; Winemiller
1999); a registry study (n = 1) (Gagner 2012); the single modali-
ties group used either heparin or IPC (n = 1) (Kumaran 2008); as-
pirin was used for thromboprophylaxis (n = 2) (Lieberman 1994;
Westrich 1996), and only aggregated VTE rates and not separate
DVT and PE rates were provided (n = 1) (Mehta 2010).
Ongoing studies
Three additional studies were identified as ongoing (CHICTR-
IPR-15007324; ISRCTN44653506 and NCT02040103;
NCT00740987). See Characteristics of ongoing studies.
Risk of bias in included studies
See Figure 2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Overall risk of bias was mostly unclear or high.
Allocation
The randomization method was unclear in 10 of the 15 RCTs
(Cahan 2000; Dickinson 1998; Edwards 2008; Eisele 2007;
Silbersack 2004; Siragusa 1994; Stannard 1996; Westrich 2006;
Windisch 2011; Yokote 2011). The studies that provided this in-
formation used random tables (Ramos 1996), a centralized com-
puter-generated schedule (Sakai 2016; Song 2014; Turpie 2007),
and sealed envelopes (Woolson 1991). As a result, the quality of
RCTs was mostly poor regarding selection bias, which was gen-
erally at high risk. By definition all quasi-randomized trials and
CCTs had a high risk for random sequence generation and there-
fore selection bias.
A high risk for allocation concealment was evident in nine studies
(Bigg 1992; Borow 1983; Bradley 1993; Kurtoglu 2003; Sakai
2016; Sieber 1997; Song 2014; Tsutsumi 2012; Westrich 2005).
Only Turpie 2007 had a low risk for allocation bias. In the re-
maining studies the risk of selection bias due to allocation con-
cealment was unclear (Cahan 2000; Dickinson 1998; Edwards
2008; Eisele 2007; Ramos 1996; Silbersack 2004; Siragusa 1994;
Stannard 1996; Westrich 2006; Windisch 2011; Woolson 1991;
Yokote 2011).
Blinding
Ahigh risk of performance biaswas evident in all studies except two
recent RCTs, which were double-blinded (Turpie 2007; Yokote
2011). The remaining studies were judged as being at high risk
because of the lack of use of a placebomedication or device. Blind-
ing of outcome assessment was reported by six studies (Bradley
1993; Kurtoglu 2003; Stannard 1996; Turpie 2007; Windisch
2011; Yokote 2011), while in the remaining studies there was un-
clear evidence of detection bias. This lack of blinding may have
affected the detection of DVT or PE and potentially increase the
heterogeneity of the results.
Incomplete outcome data
A total of 324 participants (3.5%) were excluded. One study ex-
cluded eight participants due to non-compliance, confinement to
bed for more than one week, premature transfer to a different in-
stitution, or re-operation or discharge from hospital without ul-
trasonography (Silbersack 2004). One study excluded 11 partici-
pants because of a protocol violation (discharged before the ultra-
sound) (n = 6), or because they did not receive the correct study
medication (n = 5) (Westrich 2006). A third study excluded 24
participants because inclusion or exclusion criteria were not met,
informed consent was withdrawn, adverse events occurred, or for
other reasons not stated (Turpie 2007). Three additional studies
excluded 3, 43 and 235 participants respectively (Edwards 2008;
Ramos 1996; Song 2014).
A total of 78 participants (0.85%) were lost to follow-up. One
study reported a 26.5% loss to follow up (Westrich 2006), which
was 0.8% of the total number of participants in this systematic
review; however, short-term data were provided.
Selective reporting
No findings of selective reporting were identified.
Other potential sources of bias
Three studieswere considered as being at high risk for other sources
of bias (Dickinson 1998; Edwards 2008; Sakai 2016). Reasons
for this were because they were prematurely stopped (Dickinson
1998; Sakai 2016); or had a large number of post-randomization
exclusions (Edwards 2008).
Effects of interventions
See: Summary of findings for the main comparison IPC
plus pharmacological prophylaxis versus IPC alone; Summary
of findings 2 IPC plus pharmacological prophylaxis versus
pharmacological prophylaxis alone
Intermittent pneumatic leg compression (IPC) plus
pharmacological prophylaxis versus IPC alone
See Summary of findings for the main comparison.
Twelve of the included studies evaluated the role of combined
modalities on the incidence of symptomatic PE (Bigg 1992; Borow
1983; Cahan 2000; Dickinson 1998; Kurtoglu 2003; Sieber
1997; Song 2014; Stannard 1996; Tsutsumi 2012; Turpie 2007;
Woolson 1991; Yokote 2011). The incidence of PE was 0.79%
(10/1281) in the control group and 0.46% (8/1736) in the com-
bined group showing no difference between the combined and
control groups; OR 0.49, 95% CI 0.18 to 1.34; participants =
3017; studies = 12; Analysis 1.1. Results did not demonstrate het-
erogeneity (I2 = 0%). The quality of the evidence was downgraded
to moderate for imprecision likely due to a type II error. Fatal PE
was not reported.
Eleven studies investigated the role of combined modalities on the
incidence of DVT (Borow 1983; Cahan 2000; Dickinson 1998;
Kurtoglu 2003; Sieber 1997; Song 2014; Stannard 1996;Tsutsumi
2012; Turpie 2007; Woolson 1991; Yokote 2011). The incidence
of DVT was 4.10% (51/1243) in the control group and 2.19%
(37/1691) in the combined group showing a reduced incidence of
DVT in favor of the combined modalities group (OR 0.52, 95%
CI 0.33 to 0.82; participants = 2934; studies = 11), Analysis 1.2.
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Results did not demonstrate heterogeneity (I2 = 0%). The quality
of the evidence was downgraded to moderate for risk of attrition
bias (see sensitivity analysis below).
Six studies reported on the occurrence of symptomatic DVT (
Cahan 2000; Sieber 1997; Song 2014; Tsutsumi 2012; Turpie
2007; Yokote 2011). The incidence of symptomatic DVT was
0.48% (5/1043) in the control group and 0.54% (8/1483) in the
combined modalities group, showing no difference between the
combined and control groups (OR 0.49, 95% CI 0.16 to 1.47;
participants = 2526; studies = 6), Analysis 1.3. Results did not
demonstrate heterogeneity (I2 = 0%).
One study investigated the role of combined modalities on the
incidence of DVT using a foot IPC (Stannard 1996), but because
of a lack of events a risk estimate could not be calculated. Ten stud-
ies investigated the role of combined modalities on the incidence
of DVT using IPC other than a foot IPC (Borow 1983; Cahan
2000; Dickinson 1998; Kurtoglu 2003; Sieber 1997; Song 2014;
Tsutsumi 2012; Turpie 2007; Woolson 1991; Yokote 2011). The
incidence of DVT was 4.19% (51/1218) in the control group and
2.22% (37/1666) in the combined group showing a reduced in-
cidence of DVT in favor of the combined modalities group (OR
0.52, 95% CI 0.33 to 0.82; participants = 2884; studies = 10),
Analysis 1.4. Results did not demonstrate heterogeneity (I2 = 0%).
Seven studies reported on the incidence of bleeding in the com-
bined modalities and IPC groups (Bigg 1992; Dickinson 1998;
Song 2014; Tsutsumi 2012; Turpie 2007; Woolson 1991; Yokote
2011). The incidence of bleeding was 0.66% (7/1053) in the con-
trol (IPC) group and 4.0% (44/1102) in the combined group
showing an increase in bleeding in the combined group (OR 5.04,
95% CI 2.36 to 10.77; participants = 2155; studies = 7), Analysis
1.5. Results did not demonstrate heterogeneity (I2 = 0%). The
quality of the evidence was downgraded to moderate for indirect-
ness. Major bleeding followed a similar pattern, with an incidence
of 0.1% (1/1053) in the control (IPC) group and 1.5% (17/1102)
in the combined group (OR 6.81, 95% CI 1.99 to 23.28; partic-
ipants = 2155; studies = 7), Analysis 1.6. Results did not demon-
strate heterogeneity (I2 = 0%). The quality of the evidence was
downgraded to moderate for indirectness. Fatal bleeding during
the intervention period was not reported.
IPC plus pharmacological prophylaxis versus
pharmacological prophylaxis alone
See Summary of findings 2.
Ten studies evaluated the role of combined modalities on the in-
cidence of symptomatic PE (Borow 1983; Bradley 1993; Cahan
2000; Dickinson 1998; Edwards 2008; Ramos 1996; Sakai 2016;
Silbersack 2004; Stannard 1996; Windisch 2011). The incidence
of PE was 2.92% (50/1711) in the control group and 1.20% (22/
1833) in the combined group showing a reduction in PE in favor
of the combinedmodalities group (OR0.39, 95%CI 0.23 to 0.64;
participants = 3544; studies = 10), Analysis 2.1. Results did not
demonstrate heterogeneity (I2 = 0%). The quality of the evidence
was downgraded to moderate for risk of detection and attrition
bias (see sensitivity analysis below). Fatal PE was not reported,
except in one study, which did not provide the exact number of
deaths or the treatment group they occurred in (Ramos 1996).
Eleven studies investigated the role of combined modalities on
the incidence of DVT (Borow 1983; Bradley 1993; Cahan
2000; Dickinson 1998; Edwards 2008; Eisele 2007; Sakai 2016;
Silbersack 2004; Siragusa 1994; Stannard 1996; Windisch 2011).
The incidence of DVT was 6.20 (90/1452) in the control group
and 2.90% (41/1414) in the combined group showing no differ-
ence between the combined and control groups (OR 0.42, 95%
CI 0.18 to 1.03; participants = 2866; studies = 11), Analysis 2.2.
Results demonstrated significant heterogeneity (I2 = 68%). The
quality of the evidence was downgraded to moderate for risk of
selection, detection and other bias (see sensitivity analysis below).
Five studies reported on the occurrence of symptomatic DVT
(Cahan 2000; Edwards 2008; Eisele 2007; Sakai 2016; Windisch
2011). The incidence of symptomatic DVT was 0.43% (5/1157)
in the control group and 0.43% (5/1155) in the combined group
showing no difference between the combined and control groups
(OR 1.02, 95% CI 0.29 to 3.54; participants = 2312; studies =
5), Analysis 2.3. Results did not demonstrate heterogeneity (I2 =
0%).
Four studies investigated the role of combined modalities on the
incidence of DVT using a foot IPC (Bradley 1993; Sakai 2016;
Stannard 1996; Windisch 2011). The incidence of DVT was
16.37% (28/171) in the control group and 13.07% (20/153) in
the combined group showing no difference between the combined
and control groups (OR 0.40, 95% CI 0.05 to 3.47; participants
= 324; studies = 4). Results demonstrated significant heterogene-
ity (I2 = 81%). Seven studies investigated the role of combined
modalities on the incidence of DVT using IPC other than a foot
IPC (Borow 1983; Cahan 2000; Dickinson 1998; Edwards 2008;
Eisele 2007; Silbersack 2004; Siragusa 1994). The incidence of
DVT was 4.83% (62/1281) in the control group and 1.67% (21/
1261) in the combined group showing a reduced incidence of
DVT in favor of the combined modalities group (OR 0.39, 95%
CI 0.16 to 0.96; participants = 2542; studies = 7), Analysis 2.4.
Results did not demonstrate significant heterogeneity (I2 = 51%).
Three studies reported on the incidence of bleeding in the com-
bined and pharmacological prophylaxis groups (Dickinson 1998;
Sakai 2016; Windisch 2011). These studies showed no difference
in bleeding rates between the combined group (8/121, 6.6%) and
the control group (10/123, 8.1%) (OR 0.80, 95% CI 0.30 to
2.14; participants = 244; studies = 3), Analysis 2.5. Results did
not demonstrate heterogeneity (I2 = 0%). The quality of the ev-
idence was downgraded to very low for risk of bias due to blind-
ing, indirectness.and imprecision. There was also no difference in
major bleeding rates between the combined group (6/121, 5.0%)
and the control group (5/123, 4.1%) (OR 1.21, 95% CI 0.35 to
4.18; participants = 244; studies = 3), Analysis 2.6. Results did
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not demonstrate heterogeneity (I2 = 0%). Fatal bleeding during
the intervention period was not reported.
IPC plus pharmacological prophylaxis versus IPC plus aspirin
Three studies evaluated the role of combined IPC plus pharma-
cological prophylaxis versus IPC plus aspirin on the incidence of
symptomatic PE (Westrich 2005;Westrich 2006;Woolson 1991).
The studies showed a similar frequency of PE in the IPC plus as-
pirin control (2/268, 0.75%) and IPC plus pharmacological pro-
phylaxis treatment groups (0/337, 0%) (OR 0.33, 95%CI 0.03 to
3.19; participants = 605; studies = 3), Analysis 3.1. Results did not
demonstrate heterogeneity (I2 = 0%). Fatal PE was not reported.
The same studies investigated the role of combined modalities on
the incidence of DVT. The studies showed a similar frequency
in DVT in the IPC plus aspirin control (32/268, 11.9%) and
IPC plus pharmacological prophylaxis treatment groups (30/337,
8.9%) (OR 0.83, 95%CI 0.48 to 1.42; participants = 605; studies
= 3), Analysis 3.2. Results did not demonstrate heterogeneity (I2
= 0%).
One study reported on the occurrence of symptomatic DVT (
Westrich 2005), but because of the lack of events, a risk estimate
could not be calculated (Analysis 3.3). No foot IPC was used in
this comparison and therefore subgroup analysis was not possible.
Three studies evaluated the role of combined IPC plus pharma-
cological prophylaxis versus IPC plus aspirin on the incidence of
bleeding (Westrich 2005; Westrich 2006; Woolson 1991). The
studies showed a similar frequency in bleeding in the IPC plus
aspirin control (2/275, 0.7%) and IPC plus pharmacological pro-
phylaxis treatment groups (4/341, 1.2%) (OR 1.23, 95% CI 0.27
to 5.53; participants = 616; studies = 3), Analysis 3.4. Results did
not demonstrate heterogeneity (I2 = 0%). These studies showed
also a similar frequency in major bleeding in the IPC plus as-
pirin control (2/275, 0.7%) and IPC plus pharmacological pro-
phylaxis treatment groups (2/341, 0.6%) (OR 0.80, 95% CI 0.15
to 4.17; participants = 616; studies = 3), Analysis 3.5. Results did
not demonstrate heterogeneity (I2 = 0%). Fatal bleeding during
the intervention period was not reported.
Subgroup analysis according to surgery type
IPC plus pharmacological prophylaxis versus IPC in
orthopedic and non-orthopedic participants
Three studies evaluated the role of combined modalities on the
incidence of symptomatic PE in orthopedic participants (Stannard
1996; Woolson 1991; Yokote 2011). There were no events, which
precluded any comparison (Analysis 4.1).
Nine studies evaluated the role of combined modalities versus IPC
alone on the incidence of symptomatic PE in participants not
undergoing orthopedic surgery (Bigg 1992; Borow 1983; Cahan
2000; Dickinson 1998; Kurtoglu 2003; Sieber 1997; Song 2014;
Tsutsumi 2012; Turpie 2007). These studies showed no difference
in the incidence of PE ( 0.91% (10/1097) in the control group
and 0.54% (8/1475) in the combined treatment group(OR 0.49,
95% CI 0.18 to 1.34; participants = 2572; studies = 9), Analysis
4.1. Results did not demonstrate heterogeneity (I2 = 0%).
It was not possible to test for differences between the orthopedic
and non-orthopedic subgroups for PE incidence as no PE events
were reported in the orthopedic subgroup.
The same three studies evaluated the role of combined modalities
on the incidence of DVT in orthopedic participants (Stannard
1996;Woolson 1991; Yokote 2011). These studies showed no dif-
ference in the incidence of DVT (8.15% (15/184) in the control
group and 6.51% (17/261) in the combined treatment group OR
0.80, 95% CI 0.38 to 1.69; participants = 445; studies = 3), Anal-
ysis 4.2. Results did not demonstrate heterogeneity (I2 = 0%).
Eight studies evaluated the role of combined modalities on the
incidence of DVT in participants not under going orthopedic
surgery (Borow 1983; Cahan 2000; Dickinson 1998; Kurtoglu
2003; Sieber 1997; Song 2014; Tsutsumi 2012; Turpie 2007).
These studies showed a reduction in DVT for the combined treat-
ment group (3.40% (36/1059) in the control group and 1.40%
(20/1430) in the combined treatment group, OR 0.41, 95% CI
0.23 to 0.73; participants = 2489; studies = 8), Analysis 4.2. Re-
sults did not demonstrate heterogeneity (I2 = 0%).
No difference was detected between the orthopedic and non-or-
thopedic subgroups for DVT incidence (P = 0.16).
IPC plus pharmacological prophylaxis versus
pharmacological prophylaxis in orthopedic and non-
orthopedic participants
Six studies evaluated the role of combined modalities on the in-
cidence of symptomatic PE in orthopedic participants (Bradley
1993; Edwards 2008; Sakai 2016; Silbersack 2004; Stannard 1996;
Windisch 2011). These trials showed no difference in PE (0.54%
(2/370) in the control group and 0.28% (1/362) in the combined
treatment group, OR 0.58, 95% CI 0.08 to 4.49; participants =
732; studies = 6), Analysis 5.1. Results did not demonstrate het-
erogeneity (I2 = 0%).
Four studies evaluated the role of combinedmodalities versus phar-
macological prophylaxis alone on the incidence of symptomatic
PE in participants not undergoing orthopedic surgery (Borow
1983; Cahan 2000; Dickinson 1998; Ramos 1996). These stud-
ies showed a reduction in incidence of PE in favor of the com-
bined treatment group; 3.58% (48/1341) in the control group and
1.43% (21/1471) in the combined treatment group (OR 0.38,
95% CI 0.22 to 0.63; participants = 2812; studies = 4), Analysis
5.1. Heterogeneity could not be calculated as only one study re-
ported any PE events (Ramos 1996).
No difference was detected between the orthopedic and non-or-
thopedic subgroups for PE incidence (P = 0.68).
Eight studies investigated the role of combined modalities on
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the incidence of DVT in orthopedic participants (Bradley 1993;
Edwards 2008; Eisele 2007; Sakai 2016; Silbersack 2004; Siragusa
1994; Stannard 1996; Windisch 2011). These trials showed a re-
duction in incidence of DVT in favor of the combined treatment
group; 6.66% (87/1307) in the control group to 2.79% (36/1298)
in the combined treatment group OR 0.32, 95% CI 0.12 to 0.86;
participants = 2605; studies = 8), Analysis 5.2. Results did demon-
strate significant heterogeneity (I2 = 73%), and a random-effects
model was used.
Three studies investigated the role of combined modalities ver-
sus pharmacological prophylaxis alone on the incidence of DVT
in participants not undergoing orthopedic surgery (Borow 1983;
Cahan 2000; Dickinson 1998). These trials showed a similar fre-
quency in DVT, 2.07% (3/145) in the control group and 4.31%
(5/116) in the combined treatment group, OR 1.77, 95%CI 0.30
to 10.58; participants = 261; studies = 3), Analysis 5.2. Results
demonstrated low heterogeneity (I2 = 14%).
No difference was detected between the orthopedic and non-or-
thopedic subgroups for DVT incidence (P = 0.1).
IPC plus pharmacological prophylaxis versus IPC plus aspirin
- subgroups
The three studies in this comparison all included orthopedic
participants and therefore subgroup analyses between orthopedic
and non-orthopedic groups were not possible (Westrich 2005;
Westrich 2006;Woolson 1991). Details of the studies in this com-
parison are reported above and in Analysis 3.1 and Analysis 3.2.
Sensitivity analysis
Randomized controlled trials only - intermittent pneumatic
leg compression (IPC) plus pharmacological prophylaxis
versus IPC alone
Seven RCTs evaluated the role of combined modalities on the
incidence of symptomatic PE (Cahan 2000; Dickinson 1998;
Song 2014; Stannard 1996; Turpie 2007; Woolson 1991; Yokote
2011). These trials showednodifference in incidence of PE; 0.41%
(4/980) in the control group to 0.19% (2/1043) in the combined
group, RR 0.51, 95%CI 0.09 to 2.76; participants = 2023; studies
= 7), Analysis 6.1. Results did not demonstrate heterogeneity (I2
= 0%).
The same RCTs evaluated the role of combined modalities on the
incidence of DVT (Cahan 2000; Dickinson 1998; Song 2014;
Stannard 1996; Turpie 2007;Woolson 1991; Yokote 2011). These
trials showed a reduction in DVT in favor of the combined treat-
ment group; 4.40% (43/978) in the control group and 2.72%
(28/1030) in the combined treatment group, RR 0.56, 95% CI
0.35 to 0.90; participants = 2008; studies = 7), Analysis 6.2. Low
heterogeneity was present (I2 = 19%).
Randomized controlled trials only - IPC plus
pharmacological prophylaxis versus pharmacological
prophylaxis alone
Eight RCTs evaluated the effect of combined modalities on
the incidence of symptomatic PE (Cahan 2000; Dickinson
1998; Edwards 2008, Ramos 1996; Sakai 2016; Silbersack 2004;
Stannard 1996; Windisch 2011). These trials showed a reduction
in the incidence of PE in favor of the combined treatment group;
3.20% (50/1560) in the control group and 1.28% (22/1725) in
the combined treatment group, RR 0.40, 95% CI 0.24 to 0.65;
participants = 3285; studies = 8), Analysis 7.1. Results did not
demonstrate heterogeneity (I2 = 0%).
Nine RCTs investigated the role of combined modalities on the
incidence of DVT (Cahan 2000; Dickinson 1998; Edwards 2008,
Eisele 2007; Sakai 2016; Silbersack 2004; Siragusa 1994; Stannard
1996; Windisch 2011). These trials showed no difference in inci-
dence of DVT; 5.84% (76/1301) in the control group and 2.91%
(38/1306) in the combined treatment group, RR 0.49, 95% CI
0.19 to 1.26; participants = 2607; studies = 9), Analysis 7.2. Sub-
stantial heterogeneity was present (I2 = 76%).
Randomized controlled trials only - IPC plus
pharmacological prophylaxis versus IPC plus aspirin
Two RCTs evaluated the role of these combined modalities on the
incidence of symptomatic PE (Westrich 2006; Woolson 1991).
These trials showed no difference in PE; 1.00% (2/201) in the
IPC plus aspirin control group and 0% (0/204) in the IPC plus
pharmacological prophylaxis treatment group,RR 0.33, 95% CI
0.03 to 3.17; participants = 405; studies = 2), Analysis 8.1. Results
did not demonstrate heterogeneity (I2 = 0%).
The same trials investigated the role of combinedmodalities on the
incidence of DVT. These showed no difference in DVT; 14.92%
(30/201) in the IPC plus aspirin control group and 12.25% (25/
204) in the PCplus pharmacological prophylaxis treatment group,
RR 0.81, 95% CI 0.50 to 1.33; participants = 405; studies = 2),
Analysis 8.2. Results did not demonstrate heterogeneity (I2 = 0%).
Exclusion of studies with risk of bias
Assessing the included trials for risk of bias showed a high number
of studies at high risk for performance bias and at unclear risk for
selection and detection bias. See Figure 2 and Figure 3.
Below we report those analyses that show a change in direction of
the effect when high risk of bias studies were excluded from the
analyses. No change in direction of effect were identified for the
other analyses.
Sensitivity analysis excluding studies at high risk for selection bias
(random sequence generation issues: Bigg 1992; Borow 1983;
Bradley 1993; Kurtoglu 2003; Sieber 1997; Tsutsumi 2012;
Westrich 2005), revealed in Analysis 5.2 that incidence of DVT
in orthopedic participants (OR 0.32, 95% CI 0.12 to 0.86) was
no longer significant (OR 0.34, 95% CI 0.11 to 1.03).
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Sensitivity analyses excluding studies at high risk for selection
bias (allocation concealment issues: Bigg 1992; Borow 1983;
Bradley 1993; Kurtoglu 2003; Sakai 2016; Sieber 1997; Song
2014; Tsutsumi 2012; Westrich 2005) revealed that Analysis 2.2
(incidence of DVT for the comparison IPC plus pharmacological
prophylaxis versus pharmacological prophylaxis alone (OR 0.42,
95% CI 0.18 to 1.03; P = 0.06) became significant (OR 0.32,
95% CI 0.12 to 0.84; P = 0.02). Analysis 7.2 showed that the
incidence of DVT for the comparison IPC plus pharmacological
prophylaxis versus pharmacological prophylaxis alone with RCTs
only (RR 0.49, 95% CI 0.19 to 1.26) also became significant (RR
0.37, 95% CI 0.15 to 0.89).
Sensitivity analyses excluding studies with a high or unclear risk for
blinding of outcome assessment (detection bias: Bigg 1992; Borow
1983; Cahan 2000; Dickinson 1998; Edwards 2008; Eisele 2007;
Ramos 1996; Sakai 2016; Sieber 1997; Silbersack 2004; Siragusa
1994; Song 2014; Tsutsumi 2012;Westrich 2005;Westrich 2006;
Woolson 1991), revealed that Analysis 2.1 (incidence of PE for the
comparison IPC plus pharmacological prophylaxis versus phar-
macological prophylaxis alone (OR 0.39, 95% CI 0.23 to 0.64;
P = 0.0002) was no longer significant (OR 0.32, 95% CI 0.01
to 8.25; P = 0.49) and similarly in Analysis 7.1 for RCTs only
(OR 0.33, 95% CI 0.01 to 7.81). In Analysis 2.2 (incidence of
DVT for the comparison IPC plus pharmacological prophylaxis
versus pharmacological prophylaxis alone (OR 0.42, 95%CI 0.18
to 1.03; P = 0.06) became significant (OR 0.15, 95% CI 0.04 to
0.62; P = 0.008).
Sensitivity analyses excluding studies with a high risk for attri-
tion bias (incomplete outcome data) (Song 2014; Turpie 2007),
revealed that Analysis 1.2 (incidence of DVT for the comparison
IPC plus pharmacological prophylaxis versus IPC alone; OR 0.52,
95% CI 0.33 to 0.82; P = 0.005) was no longer significant (OR
0.72, 95%CI 0.41 to 1.26; P = 0.25). A similar change in the level
of effect was seen in Analysis 4.2 for the subgroup of non-ortho-
pedic participants which showed OR 0.62, 95% CI 0.27 to 1.44),
Analysis 6.2 (OR 0.89, 95% CI 0.48 to 1.64) and Analysis 7.1
(OR 0.59, 95%CI 0.08 to 4.40) both for RCTs only. However for
Analysis 5.1, no studies were left for the non-orthopedic subgroup
after removing Ramos 1996. For Analysis 2.1 the incidence of PE
for the comparison IPC plus pharmacological prophylaxis versus
pharmacological prophylaxis (OR 0.39, 95% CI 0.23 to 0.64; P
= 0.0002) was no longer significant (OR 0.58, 95% CI 0.08 to
4.49; P = 0.60).
Sensitivity analysis excluding studies with a high risk for other bias
(Dickinson 1998; Edwards 2008; Sakai 2016) revealed that Anal-
ysis 2.2 (incidence of DVT for the comparison IPC plus pharma-
cological prophylaxis versus pharmacological prophylaxis) became
significant (OR 0.20, 95% CI 0.11 to 0.37; I2 = 29%) and so did
Analysis 7.2 (RR 0.22, 95% CI 0.06 to 0.79) comparing RCTs
only.
Sensitivity analysis excluding studies with a high risk for perfor-
mance bias (blinding of participants and personnel) was not per-
formed because only two studies were deemed to be of low risk of
performance bias (Turpie 2007; Yokote 2011).
Regarding the outcomes of bleeding and major bleeding, sensitiv-
ity analyses excluding studies with a high risk for all types of bias
was performed only for the comparison of combined modalities
versus IPC because the number of studies reporting on bleeding
in the remaining comparisons was insufficient to show meaning-
ful results. No changes were observed in the direction of effect of
bleeding when excluding studies with a high risk for all types of
bias.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Does combined intermittent pneumatic compression (IPC) plus pharmacological prophylaxis increase prevention of venous thromboembolism compared with pharmaco-
logical prophylaxis alone?
Patient or population: pat ients undergoing surgery or at risk of developing VTE because of other reasons (e.g. trauma)
Settings: hospital (surgery, trauma or ICU stay)
Intervention: combined IPC plus pharmacological prophylaxis
Comparison: pharmacological prophylaxis alone
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Single modalities Combined modalities
Incidence of PEa 29 per 1000 12 per 1000 (7 to 19) OR 0.39 (0.23 to 0.64) 3544 (10) ⊕⊕⊕©
moderate1
Incidence of DVTb 62 per 1000 27 per 1000 (12 to 64) OR 0.42 (0.18 to 1.03) 2866 (11) ⊕⊕⊕©
moderate2
Incidence of bleedingc 81 per 1000 66 per 1000 (26 to 159) OR 0.8 (0.3 to 2.14 244 (3) ⊕©©©
very low3
Incidence of major
bleedingd
41 per 1000 49 per 1000 (15 to 150) OR 1.21 (0.35 to 4.18) 244 (3) ⊕©©©
very low3
* The basis for the assumed risk was the average risk in the single modalit ies group (i.e. the number of part icipants with events divided by total number of part icipants of the
single modalit ies group included in the meta-analysis). The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the comparison group and
the relative effect of the intervent ion (and its 95% CI)
CI: conf idence interval;DVT: deep vein thrombosis;IPC: interm it tent pneumatic compression; OR: odds rat io; PE: pulmonary embolism; VTE: venous thromboembolism
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
a PE assessed by pulmonary angiography or scint igraphy, computed tomography (CT), angiography, or autopsy
b DVT assessed by ascending venography, I-125 f ibrinogen uptake test, and ultrasound scanning
c any type of bleeding as described by the study authors
d major bleeding as def ined by the study authors, but usually located at the surgical site or in a crit ical organ or site, requiring
intervent ion or transfusion of at least units of blood, or leading to death
1 Downgraded by one level due to risk of detect ion and attrit ion bias af fect ing ef fect est imate as shown by sensit ivity analysis
2 Downgraded by one level, due to risk of select ion, detect ion and other bias af fect ing ef fect est imate as shown by sensit ivity
analysis. Heterogeneity explained by detect ion and other bias
3 Downgraded by three levels due to risk of bias due to blinding (none of the studies in this comparison are double blind),
indirectness (report ing of bleeding outcomes (major and minor bleeding) was not uniform across the studies, with some
studies report ing on blood loss during the procedures or through the drains or providing rates for postoperat ive bleeding and
def init ions used were not uniform) and imprecision (small number of part icipants and relat ively few events
1
9
C
o
m
b
in
e
d
in
te
rm
itte
n
t
p
n
e
u
m
a
tic
le
g
c
o
m
p
re
ssio
n
a
n
d
p
h
a
rm
a
c
o
lo
g
ic
a
l
p
ro
p
h
y
la
x
is
fo
r
p
re
v
e
n
tio
n
o
f
v
e
n
o
u
s
th
ro
m
b
o
e
m
b
o
lism
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
6
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
D I S C U S S I O N
Summary of main results
Our review showed that combined modalities are more effective
than single modalities in reducing the incidence of deep vein
thrombosis (DVT) when compared to compression and incidence
of pulmonary (PE)when compared to anticoagulation.Our review
showed no difference between combined and single modalities in
the incidence of PE when compared with compression alone and
DVT when compared with anticoagulation alone. For PE this was
likely caused by the low number of events and can be attributed
to a type II error, i.e. an incorrect retention of the null hypothesis.
The latter also applies to the studies that investigated the combi-
nation of compression plus anticoagulant with compression plus
aspirin. However the quality of evidence for the research that sup-
ports these conclusions was judged to be moderate as a result of
bias being present in several domains. The addition of an antico-
agulant to IPC, however, increased the risk of bleeding compared
to IPC alone, a side effect not observed for IPC when added to an-
ticoagulation, as indeed expected for a physical method of throm-
boprophylaxis. These findings highlight the need to tailor the use
of additional pharmacological thromboprophylaxis in patients at
low risk for bleeding or those where bleeding does not have catas-
trophic consequences. This issue deserves further study since the
criteria for major bleeding were not uniform across the studies,
with some of them reporting on blood loss during the procedures
or through the drains nor providing rates for postoperative bleed-
ing.
Themechanism responsible for the improved effectiveness of com-
binedmodalities may be attributed to the fact that DVT is amulti-
factorial process. Virchow in 1856 suggested that venous stasis, co-
agulopathy and endothelial injury are all causes of VTE (Virchow
1856). By treating the different causes of VTE it is expected to
improve efficacy in DVT prevention. Rosendaal more recently
extended Virchow’s theory by proposing a model of risk factors,
which considered the importance of the additive role and inter-
action of multiple risk factors (multiple hit model) (Rosendaal
1999). Based on the additive role of mechanical and pharmaco-
logical modalities, the results of this review suggest that venous
stasis and hypercoagulopathy are truly independent risk factors.
IPC reduces venous stasis by producing active flow enhancement
(Kakkos 2005), and also increases tissue factor pathway inhibitor
(TFPI) plasma levels (Chouhan 1999). Unfractionated and low
molecular weight heparin inhibit factor X. These totally different
mechanisms of action are most likely responsible for the synergy
between these two modality types.
Subgroup analysis confirmed the efficacy of adding compression
to anticoagulation in DVT prevention in orthopedic participants,
known to suffer from venous stasis, and also the efficacy of adding
anticoagulation to compression in DVT prevention in non-or-
thopedic participants, known to have frequently hypercoagulation
due to the presence of sepsis, malignancy or other reasons. How-
ever the studies were underpowered regarding the other compar-
isons and also for the outcome of PE, with the exception of the
comparison combined modalities versus anticoagulation in non-
orthopedic participants. Interestingly, some comparisons became
significant after removing studies deemed to be high risk for bias,
as presented in the results section of this review. Similarly, com-
parisons for symptomatic DVT were also underpowered and fur-
ther studies may be required. Interestingly, the subgroup analysis
of the comparison IPC plus pharmacological prophylaxis versus
pharmacological prophylaxis, restricted to IPCs other than foot
IPCs was significantly in favor of the combined modalities, unlike
the analysis of all IPCs combined, perhaps because the potentially
less effective foot IPCs were not included.
Pulmonary embolism risk-reduction rates were mostly consistent
across the studies with no heterogeneity, perhaps because symp-
tomatic PE is a clinically significant complication. In contrast,
some heterogeneity was noted in the results on DVT reduction,
particularly in non-orthopedic participants. This might have been
related to the fact that methodological quality of the assessed stud-
ies was low, with allocation concealment usually being unclear and
performance bias usually being high. An alternative explanation
is that the heterogeneity of the included participants who under-
went various surgical procedures resulted in a variable risk of DVT.
Indeed subgroup analysis by patient characteristic provided results
with better heterogeneity.
The results of our review endorse the recommendations of the ve-
nous thromboembolism prevention guidelines that high-risk pa-
tients should receive multimodal prophylaxis (Gould 2012; NICE
2009; Nicolaides 2013).
Overall completeness and applicability of
evidence
The studies included in this reviewwere carried out in awide range
of patient groups undergoing orthopedic but also urological, car-
diothoracic, general surgery neurosurgery, gynecology procedures
and trauma patients. Most of the participants had a high-risk pro-
cedure or condition and, therefore, the results of this review are not
necessarily applicable to different patient groups, where a much
lower risk may reduce the absolute risk reduction with combined
modalities.
In an effort to investigate the applicability of combined modalities
in orthopedic and non-orthopedic participants, subgroup analysis
was performed, confirming the efficacy of adding compression to
anticoagulation in orthopedic patients, and the efficacy of adding
anticoagulation to compression in non-orthopedic patients, re-
sults that indicate a need for further research in particular patient
populations. Since studies on combined modalities are mostly per-
formed in patients at a high risk for VTE, the absolute benefit that
would be observed is expected to be much lower in moderate-risk
patients, calling for cost-effectiveness calculations and studies.
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Additionally, it should be noted that the various IPC typesmay not
have the same effectiveness and should not be used interchange-
ably, for example foot pumps versus calf or calf and thigh leggings,
taking into account the results of Analysis 2.4.
A potential confounding factor in the present review is the con-
current use of elastic stockings, very often used together with IPC.
Also, it should be mentioned that medical (non-surgical) patients
were not included in the present review because such studies were
not identified by the literature searches.
Reporting of bleeding outcomes (major and minor bleeding) was
not uniform across the studies, with some studies reporting on
blood loss during the procedures or through the drains or pro-
viding rates for postoperative bleeding. Definitions used were also
not uniform. This issue deserves further study.
Quality of the evidence
This review included some 9137 participants who were studied in
22 trials (15 RCTs). This provided a body of evidence to investi-
gate our hypothesis that combined modalities are more effective
than their single counterparts. However, risk for performance bias
was high in most studies and risk for selection and detection bias
was mostly unclear. Nevertheless, the results of the present meta-
analysis update are generally consistent with a low amount of het-
erogeneity in almost all comparisons.
Using GRADE assessment, the quality of evidence for DVT and
PE prevention with combined modalities is considered as being
moderate. See Summary of findings for the main comparison and
Summary of findings 2. Regarding PE for the comparison of com-
bined modalities with IPC alone, the quality of the evidence is
downgraded due to very few events with only 4/12 studies con-
tributing to the effect estimate leading to imprecision probably
because of a type II error. For the comparison of combined modal-
ities with anticoagulation, the quality of the evidence for PE is
downgraded due to detection bias as a sensitivity analysis exclud-
ing studies at high or unclear risk of detection bias no longer
show a reduction in the incidence of PE. Possible explanations
for these two observations regarding PE include the elimination
of low quality research leading to more accurate albeit negative
results and also reduction of the number of studies and events (i.e.
reduced the overall power to detect a difference). Since PE is a
form of VTE, like DVT, we think that the second explanation is
more rational than the first one. For DVT for both comparisons
(combined modalities compared with IPC or anticoagulation) the
quality of the evidence is downgraded to moderate due to risk of
bias.
The quality of the evidence for bleeding and major bleeding for
the comparison combined modalities versus IPC is moderate. The
quality of the evidence was downgraded for indirectness as defini-
tions of bleeding and the reporting of bleeding outcomes was not
uniform across studies.
The quality of the evidence for bleeding and major bleeding for
the comparison combined modalities versus pharmacological pro-
phylaxis is very low. The quality of the evidence is downgraded for
risk of bias due to blinding, indirectness (because the definition
of bleeding and reporting of bleeding outcomes was not uniform
across studies) and imprecision (due to the small number of par-
ticipants and few events).
Potential biases in the review process
The review authors have made an enormous effort to identify
potential trials for inclusion in the present review. Publication bias
still could have limited the validity of our results.
This review set out to assess RCTs and CCTs. Many of the CCTs
are old and the reporting of the study methodology is often poor.
In addition, patient care and standard practice has changed con-
siderably since then. When assessing the incidence of DVT and
PE in RCTs only the overall direction and size of the effects were
not affected. This was likely caused by the fact that many CCTs
did not contribute to the analysis due to small number of reported
events. However, when sufficient RCTs become available to per-
form meaningful analyses of the planned subgroups we will con-
sider including RCTs only.
The review assessed symptomatic or asymptomatic DVT and
symptomatic PE as outcomes. In future updates, data permitting,
we will add proximal DVT and clinically important VTE (prox-
imal DVT and symptomatic PE) as additional important out-
comes.
In order to be as inclusive as possible and because not all studies
reported on the type of IPC devices used, we included all IPC
devices. This resulted in including somedevices thatmay no longer
be used in some parts of the world.
We performed no formal assessment of side effects of IPC. How-
ever, from the included studies we note these were rarely encoun-
tered and recorded by the studies. We will look into this in more
detail in future updates.
Agreements and disagreements with other
studies or reviews
The results presented here agree with previous systematic meta-
analyses on this topic (Ho 2013; Kakkos 2012; Sobieraj 2013;
Zareba 2014), which showed that combined modalities are sig-
nificantly better than single prophylactic modalities. The studies
included in these reviews were mostly restricted to a particular
patient category or were limited by the fact that they used IPC
interchangeably with elastic stockings, which is a limitation when
interpretation of the results is attempted.
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
Moderate quality evidence suggests that combining IPC with
pharmacological prophylaxis, compared with IPC or pharmaco-
logical prophylaxis alone, decreases the incidence of DVT when
compared to compression, and incidence of PE when compared
to anticoagulation. Moderate quality evidence suggests that there
is no difference between combined and single modalities in the in-
cidence of PE when compared with compression alone and DVT
when compared with anticoagulation alone. The quality of evi-
dence for incidence of PE and DVTwas downgraded to moderate
due to risk of bias in study methodology and imprecision, high-
lighting the need for further research. Moderate quality evidence
suggests the addition of an pharmacological prophylaxis to IPC,
increased the risk of bleeding compared to IPC alone, a side effect
not observed for IPC when added to pharmacological prophylaxis
(very low quality evidence), as expected for a physical method
of thromboprophylaxis. The quality of evidence for bleeding was
downgraded to moderate or very low due to risk of bias in study
methodology and indirectness, highlighting the need for further
research.The results of the current review agree with current guide-
line recommendations for hospitalised patients at risk of devel-
oping VTE. More studies on the role of combined modalities in
VTE prevention are urgently needed, taking also into account the
increased bleeding rates after anticoagulation is added to IPC.
Implications for research
Most patients who received combined modalities in the studies re-
viewed were at high risk of developing VTE. Although the relative
VTE reduction was large in this patient group, the same cannot be
extrapolated for patients at moderate risk. Future studies should
address this question and also take into account cost-effectiveness
issues; looking at benefits in terms of reduced hospital stay, re-
habilitation, mortality and long-term complications, for example
post-thrombotic syndrome, which add to the burden of disability
in the community in the long term. Since the total number of
RCTs evaluated in the current review was relatively small, partic-
ularly in certain subgroups, future research using RCTs in other
patient groups (such as patients with stroke or medical ICU pa-
tients) and confirmatory RCTs are warranted. Nevertheless, cost-
effectiveness for combined modalities has been demonstrated in
certain high risk groups by the NICE guidelines (NICE 2009).
Cost-effectiveness analysis should be performed in order to define
the impact of this policy on health economics in both high-risk
and moderate-risk patients.
More studies on the role of combined modalities (as opposed
to pharmacological prophylaxis alone) in the prevention of pul-
monary embolism are urgently needed.
Future research should also aim to use standardised bleeding crite-
ria such as those defined by the International Society on Throm-
bosis and Haemostasis (Schulman 2010).
Further research should compare the efficacy of improved single
modalities, including more effective schedule changes, with their
combinations (Eriksson 2001; Kakkos 2005; King 2007; Eriksson
2008).Only one study in the present review used edoxaban, one of
the new direct oral anticoagulants (Sakai 2016). Further research
on the effect of combined use of recently introduced, improved
prophylactic modalities is justified.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bigg 1992
Methods Study design: controlled clinical trial
Method of randomisation: study was planned to be randomized and method of planned
randomizations was stated as patient order
Concealment of allocation: none stated
Exclusions: none
Losses to follow up: none
Intention-to-treat analysis: yes
Participants Country: USA
Number of participants: 68, intervention group 32; control group 36
Age (mean, years): intervention group 67; control group 65
Sex: male
Inclusion criteria: radical retropubic prostatectomy with bilateral pelvic prostatectomy
for clinically localized prostate cancer
Exclusion criteria: none stated
Interventions Intervention group: unfractionated heparin (5000 iu BID, subcutaneously) and sequen-
tial compression devices with elastic stockings
Control group: sequential compression devices with elastic stockings
Outcomes Symptomatic PE, confirmed with ventilation-perfusion scan
Notes The study was planned to be randomized but due to administrative errors the randomi-
sation protocol was violated
Sequential compression devices were started in the operating room and discontinued
when the patients were ambulatory, usually 18 hours postoperatively
Heparin was started two hours before the operation and was continued for 7 days or the
time of discharge
Study was discontinued because of bleeding complications associated with heparin use.
No specific bleeding definitions were provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk The study was planned to be randomized
but due to administrative errors the ran-
domization protocol was violated. Method
of planned randomizations was stated as
patient order
Allocation concealment (selection bias) High risk Alternating patients received the study
medication and in most cases the surgeon
was aware of which patients received hep-
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Bigg 1992 (Continued)
arin
Blinding of participants and personnel
(performance bias)
All outcomes
High risk In most cases the surgeon was aware of
which patients received heparin, and the
same perhaps applies to the anesthesia per-
sonnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is unclear if the personnel performing the
pulmonary ventilation-perfusion scans or
angiograms were aware of which patients
received heparin
Incomplete outcome data (attrition bias)
All outcomes
Low risk No patients were lost to follow-up
Selective reporting (reporting bias) Low risk PE was the only VTE event stated in
methodology and was reported
Other bias Unclear risk No baseline characteristics, apart from age,
were provided
Borow 1983
Methods Study design: controlled clinical trial
Method of randomization: none
Concealment of allocation: not reported
Exclusions: none
Losses to follow up: none
Intention-to-treat analysis: yes
Participants Country: USA
Number of participants: 272, but only 237 of them were eligible for inclusion based on
type of prophylaxis
Age (mean, years): not reported
Sex: not reported
Inclusion criteria: general, surgery, orthopedics, gynecology, and vascular surgery
Exclusion criteria: genitourinary surgery
Interventions Intervention group: sequential compression devices and pharmacological prophylaxis
(unfractionated heparin or coumadin)
Control group: sequential compression devices or pharmacological prophylaxis (unfrac-
tionated heparin or coumadin)
Outcomes DVT diagnosed with I-125 fibrinogen scanning, IPG, Doppler ultrasound and venog-
raphy
Notes Patients who received aspirin or dextran as an exclusive pharmacological modality or
elastic stockings as an exclusive mechanical modality were not included in our review
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Borow 1983 (Continued)
All modalities were started with the preoperative medication and continued until the
patients were well ambulatory
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Patients were placed into each category in
rotation by the vascular technicians
Allocation concealment (selection bias) High risk Nodetails on the allocation procedure were
provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Placebo medications or devices were not
used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is unclear if the personnel performing
DVT testing were aware of which patients
received heparin
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients had an event reported
Selective reporting (reporting bias) Low risk DVT was the only VTE event stated in
methodology and was reported
Other bias Unclear risk No baseline characteristics were provided
Bradley 1993
Methods Study design: controlled clinical trial
Method of randomization: states that patients with an even date of birth were randomized
to receive the plantar arteriovenous impulse system on the side to be operated on
Concealment of allocation: not reported other than the radiologist who read the
venograms was blinded to patient allocation
Exclusions: none
Losses to follow up: none
Intention-to-treat analysis: yes
Participants Country: UK
Number of participants: 74
Age (mean, years): 70
Sex: not reported
Inclusion criteria: unilateral primary THA for osteoarthritis
Exclusion criteria: non-consenting patients
29Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism
(Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bradley 1993 (Continued)
Interventions Intervention group: unfractionated heparin (5000 iu BID, subcutaneously), graduated
compression stockings (TEDs), and pneumatic foot compression on the side to be op-
erated on
Control group: unfractionated heparin (5000 iu BID, subcutaneously) and graduated
compression stockings (TEDs)
Outcomes DVT on bilateral lower extremity venography performed postoperative day 12
Notes The foot pump started at the beginning of surgery and continued until discharge from
the hospital. No details were provided for heparin
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Patients with an even date of birth were
randomized to receive IPC
Allocation concealment (selection bias) High risk Patients with an even date of birth were al-
located to receive IPC - allocation therefore
predictable
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo device was used
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The radiologist who read the venograms
was blinded to patient allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk All study participants were reported in the
results section
Selective reporting (reporting bias) Low risk DVT was the only VTE outcome event
stated in methodology and was reported
Other bias Low risk Baseline characteristics were comparable
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Cahan 2000
Methods Study design: randomized controlled trial
Method of randomization: unclear
Concealment of allocation: not reported
Exclusions: none
Losses to follow up: none
Intention-to-treat analysis: yes
Participants Country: USA
Number of participants: 48
Age (mean, years): 67
Sex: 47 males, 1 female
Inclusion criteria: major intra-abdominal surgical procedures
Exclusion criteria: pre-existing venous disease, history of venous thromboembolism, pre-
operative or postoperative requirement for systemic anticoagulation (with the exception
of the 12 patients undergoing aortic aneurysm repair, who did receive systemic doses of
heparin intraoperatively)
Interventions Intervention group: subcutaneous heparin injections (5000 iu BID) combined with the
use of a thigh-length sequential pneumatic compression device (Kendall Health Care,
Manchester, Mass, USA)
Control groups:
1. subcutaneous heparin injections (5000 iu BID)
2. use of a thigh-length sequential pneumatic compression device (Kendall Health Care,
Manchester, Mass, USA)
Outcomes DVT on duplex ultrasound and also clinically evident DVT and PE
Notes Investigation on the effect of study interventions on fibrinolytic activity, but also reported
VTE outcomes
DVT prophylaxis was initiated in the operating room after induction of anesthesia
and continued until postoperative day 5 (or discharge, if this occurred sooner). If the
patient remained hospitalized after postoperative day 5, DVT prophylaxis was left to the
discretion of the primary surgeon, and the patient was no longer participating in the
research study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details provided
Allocation concealment (selection bias) Unclear risk Not provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo anticoagulants or IPC devices
were used
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Cahan 2000 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is unclear if the personnel who performed
the DVT screening were blinded to the
treatment regimens
Incomplete outcome data (attrition bias)
All outcomes
Low risk All study participants were reported in the
results section
Selective reporting (reporting bias) Low risk DVT was the only VTE outcome event
stated in methodology and was reported
Other bias Low risk No significant baseline imbalances
Dickinson 1998
Methods Study design: randomized controlled trial
Method of randomization: unclear
Concealment of allocation: not reported
Exclusions: none
Losses to follow up: none
Intention-to-treat analysis: yes
Participants Country: USA
Number of participants: 66
Age (mean, years): 47.4 (calculated)
Sex: not reported
Inclusion criteria: patients undergoing surgical treatment of intracranial neoplasms
Exclusion criteria: history of DVT or pulmonary embolism, allergy to heparin or other
anticoagulant agents, history of surgery or major trauma to the lower extremities, a con-
current condition requiring anticoagulation therapy, cranial base neoplasms and pitu-
itary adenomas
Interventions Intervention group: Enoxaparin (Lovenox; Rhône-Poulenc Rorer Pharmaceuticals) sub-
cutaneously at a dose of 30 mg in the anesthesia holding room, and continued at a dose
of 30 mg BID combined with thigh-high SCDs (Kendall), a type of IPC, functioning
on the patient before induction of anesthesia
Control groups:
1. Enoxaparin subcutaneously at a dose of 30 mg and continued at a dose of 30 mg BID
2. thigh-high SCDs (Kendall)
Outcomes DVT on duplex ultrasonography between days 1 and 3, between days 5 and 7, at the
wound check appointment between days 10 and 14, and at the 1-month follow-up
appointment
Incidence of adverse events (including bleeding) was assessed by principal investigator
by thorough review of medical records. No specific bleeding definitions were provided
Notes The IPC devices functioned throughout the surgical procedure and remained on the
patient during the postoperative period, until the patient was walking without assistance.
If the patient remained nonambulatory, the devices were discontinued at the time of
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Dickinson 1998 (Continued)
discharge from the Neurosurgery Service
Enoxaparin was started in the anesthesia holding room and was discontinued at the time
of discharge from the Neurosurgery Service
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details provided
Allocation concealment (selection bias) Unclear risk Not provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo anticoagulants or IPC devices
were used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is unclear if the personnel who performed
the DVT screening were blinded to the
treatment regimens
Incomplete outcome data (attrition bias)
All outcomes
Low risk All study participants were reported in the
results section
Selective reporting (reporting bias) Low risk DVT was the only VTE outcome event
stated in methodology and was reported
Other bias High risk The trial stopped early (enrolment was
planned for 120 subjects)
Edwards 2008
Methods Study design: randomized controlled trial
Method of randomization: unclear
Concealment of allocation: not reported
Exclusions: 10 consented patients cancelled their surgery; 33 patients were excluded for
protocol violations, such as missed ultrasound (n = 9), surgery other than THA or TKA
(n = 1), previous history of thrombosis (n = 12), prophylaxis other than LMWH (n = 8)
, and other protocol deviations (n = 3)
Losses to follow up: none
Intention-to-treat analysis: no
Participants Country: USA
Number of participants: 320
Age (mean, years): 67.3 (calculated)
Sex: 162 females, 115 males
Inclusion criteria: patients undergoing total hip or knee replacement
Exclusion criteria: not provided
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Edwards 2008 (Continued)
Interventions Intervention group: Enoxaparin (30 mg BID, starting the morning after surgery for 7
- 8 days) combined with IPC (CECT device, ActiveCare DVT; Medical Compression
Systems, Or Akiva, Israel) with calf sleeves
Control group: Enoxaparin (30 mg BID, starting the morning after surgery for 7 - 8
days)
Outcomes DVT on duplex ultrasonography before discharge and also clinically evident DVT and
PE at three months
Notes IPC was placed on the calves of the patient in the operating room and continued during
hospitalisation
Enoxaparin was started the morning after surgery and continued for 7 - 8 days
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details provided
Allocation concealment (selection bias) Unclear risk Not provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo devices were used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is unclear if the personnel who performed
the DVT screening were blinded to the
treatment regimens
Incomplete outcome data (attrition bias)
All outcomes
Low risk All study participants were reported in the
results section
Selective reporting (reporting bias) Low risk DVT and PE were VTE events stated in
methodology and were reported
Other bias High risk A large number of post-randomization ex-
clusions
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Eisele 2007
Methods Study design: randomized controlled trial
Method of randomization: not stated
Concealment of allocation: not reported
Exclusions post randomization: none
Losses to follow up: none
Intention-to-treat analysis: yes
Participants Country: Germany
Number of participants: 1803
Age (mean, years): not reported
Sex: not reported
Inclusion criteria: total joint arthroplasty (24%); knee ligamentous and meniscal repair;
tumor resection; open fixation of traumatic fractures; elective osteotomies to correct
deformities of the femur, tibia, foot, and ankle; and to treat high-impact contusion
injuries of the lower extremity, pelvis, abdomen, spine, and chest
Exclusion criteria: a surgery location that would interfere with the application of the
pneumatic compression calf cuff and existing acute DVT
Interventions Intervention group: LMWH, certoparin (3000 iu 12 hours pre-op, 12 post-op then
daily, subcutaneously), compression stockings (18 to 20 mmHg), and rapid-inflation
intermittent pneumatic compression
Control group: LMWH, certoparin (3000 iu 12 hours pre-op, 12 post-op then daily,
subcutaneously), and compression stockings (18 to 20 mmHg)
Outcomes Symptomatic DVT and DVT on duplex-color coded ultrasound performed on the day
of discharge
Notes “The DVT prophylaxis regimen was randomly assigned in the operating theatre at the
time of completion of surgery and the randomisation was stratified by age.” No infor-
mation on PE was provided
Patients in the intermittent pneumatic compression group had the intermittent pneu-
matic compression system applied to both calves in the recovery room shortly after the
completion of surgery. Intermittent pneumatic compression therapy was applied daily
during the time that the patient was confined to bed postoperatively, and it was termi-
nated at the time that the patient was able to walk
LMWH was started 12 hours preoperatively and continued throughout hospitalization
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details provided, apart from the in-
formation that it was stratified by patient
age, so that an assumption that a computer
generated sequence or the sealed envelope
method was used may be made
Allocation concealment (selection bias) Unclear risk Not reported
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo device was used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is unclear if the personnel who performed
the DVT screening were blinded to the
treatment regimens
Incomplete outcome data (attrition bias)
All outcomes
Low risk All study participants were reported in the
results section
Selective reporting (reporting bias) Low risk DVT was the only VTE event stated in
methodology and was reported
Other bias Low risk Baseline number of risk factors for deep ve-
nous thrombosis per patient were compa-
rable
Kurtoglu 2003
Methods Study design: quasi-randomized controlled trial
Method of randomization: by the last digit of year of birth
Concealment of allocation: none
Exclusions: not reported
Losses to follow up: not reported
Intention-to-treat analysis: yes
Participants Country: Turkey
Number of participants: 80
Age (mean, years): not provided
Sex: not provided
Inclusion criteria: trauma patients, at high risk for bleeding
Exclusion criteria: low risk for bleeding
Interventions Intervention group: LMWH (40 mg/day) combined with IPC
Control group: IPC
Outcomes DVT on duplex ultrasonography and clinically evident DVT and PE
Notes Information on randomization and blinding was obtained from the study authors. No
information on start and discontinuation of IPC or LMWH
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
High risk Quasi-randomized trial, randomized by the
last digit of year of birth
Allocation concealment (selection bias) High risk Quasi-randomized trial so predictable
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo anticoagulants were used
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The radiologist who performed the ultra-
sound tests was not aware of patient allo-
cation
Incomplete outcome data (attrition bias)
All outcomes
Low risk All study participants were reported in the
results section
Selective reporting (reporting bias) Low risk DVT and PE were the VTE events stated
in methodology and results were provided
Other bias Unclear risk Insufficient details were provided to allow
a conclusion to be made
Ramos 1996
Methods Study design: randomized controlled trial
Method of randomization: table of random numbers
Concealment of allocation: not reported
Exclusions post randomization: intervention group 57; control group 178
Losses to follow up: yes
Intention-to-treat analysis: no
Participants Country: USA
Number of participants: randomized 2786, completed 2551
Age (mean, years): 63.9
Sex: male 1782; female 769
Inclusion criteria: open heart surgery
Exclusion criteria: known prior DVT; bleeding complications; intraoperative death; in-
tolerance to IPC; or withdrawal of prophylaxis before full ambulation
Interventions Intervention group: unfractionated heparin (5000 iu BID, subcutaneously) and sequen-
tial compression devices
Control group: unfractionated heparin (5000 iu BID, subcutaneously)
Outcomes Symptomatic PE, confirmed by ventilation perfusion scan and/or pulmonary angiogra-
phy
Notes Both prophylactic methods were started immediately after surgery and continued for 4
to 5 days or until patients were fully ambulatory
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A table of random numbers was used
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo device was used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is unclear if the personnel performing the
pulmonary ventilation-perfusion scans or
angiograms were aware of which patients
used a compression device
Incomplete outcome data (attrition bias)
All outcomes
High risk A large number of patients were excluded
after randomization
Selective reporting (reporting bias) Low risk PE was the only VTE event stated in
methodology and was reported
Other bias Low risk Baseline characteristics were comparable
Sakai 2016
Methods Study design: randomized controlled trial
Method of randomization: computer-generated sequence
Concealment of allocation: sealed envelopes
Exclusions post randomization: none
Losses to follow up: 2 patients
Intention-to-treat analysis: no
Participants Country: Japan
Number of participants: randomized 122, completed 120
Age (mean, years): 73.7
Sex: male 20; female 100
Inclusion criteria: patients (aged ≥ 20 years) undergoing knee replacement surgery for
primary joint disease including osteoarthritis and rheumatoid arthritis
Exclusion criteria: the presence of predefined risk factors for bleeding, coagulation dis-
orders, heart failure (New York Heart Association class III or IV), significant renal dys-
function (creatinine clearance < 30 mL/min), and abnormalities in biochemical mea-
surements (aspartate aminotransferase or alanine aminotransferase ≥ 5 times the upper
limit of normal or total bilirubin≥ 2 times the upper limit of normal). Patients were also
excluded if they were scheduled to undergo bilateral joint replacement or reoperation,
were unable to walk, or had uncontrolled cardiovascular disease
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Interventions Intervention group: Edoxaban (15 mg or 30 mg OD) and a foot pump (A-V Impulse
System foot pump)
Control group: Edoxaban (15 mg or 30 mg OD)
Outcomes Symptomatic VTE by postoperative day 28 and asymptomatic DVT on compression
ultrasonography on the postoperative day 10
Bleeding: major bleeding was defined as wound hematoma or hemorrhage occurring at
a critical site and bleeding required for > 2 units of red blood cell concentrates. Minor
bleeding was defined as bleeding that did not fulfil the criteria for major bleeding
Notes Both groups also used bilateral knee-high antithromboembolic stockings
The foot pump was activated in the recovery room and used for four days
Edoxaban started 12 hours postoperatively and was used for a mean of 11.5 days
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated sequence
Allocation concealment (selection bias) High risk Sealed enveloped contained the random-
ization slip, but no statement that these
were opaque
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo device was used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information was provided on who per-
formed the ultrasound and if that person
was blinded to patient allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Minimal losses to follow-up
Selective reporting (reporting bias) Low risk DVT and PE were VTE events stated in
methodology and were reported
Other bias High risk Trial stopped prematurely
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Sieber 1997
Methods Study design: controlled clinical trial
Method of randomization: none
Exclusions: none
Losses to follow up: none
Intention-to-treat analysis: yes
Participants Country: USA
Number of participants: 579
Age (mean, years): 65
Sex: male
Inclusion criteria: patients who had pelvic lymphadenectomy with or without radical
retropubic prostatectomy
Exclusion criteria: none
Interventions Intervention group: unfractionated heparin (5000 iu BID, subcutaneously) and sequen-
tial compression devices
Control group: sequential compression devices
Outcomes Symptomatic DVT or PE
Notes Participants were assigned to heparin and control groups by the primary surgeon
Sequential compressive stockings were placed at the time of surgery and left in place for
48 hours after surgery for all patients
Heparin was started preoperatively and continued for three days
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk The type of the study (CCT) makes it high
risk for selection bias
Allocation concealment (selection bias) High risk The type of the study (CCT) makes it high
risk for selection bias
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo injection for heparin was given
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is unclear if the personnel performing di-
agnostic testing were aware of patient allo-
cation
Incomplete outcome data (attrition bias)
All outcomes
Low risk No exclusions orwithdrawalswere reported
Selective reporting (reporting bias) Low risk DVT and PE were VTE events stated in
methodology and were reported
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Other bias Unclear risk Insufficient details were provided to allow
a conclusion to be made
Silbersack 2004
Methods Study design: randomized controlled trial
Method of randomization: not reported
Concealment of allocation: not reported
Exclusions post randomization: 8
Losses to follow up: none
Intention-to-treat analysis: no
Participants Country: Germany
Number of participants: 139 randomized
Age (mean, years): 64
Sex: male 47; female 84
Inclusion criteria: primary unilateral THR or TKR
Exclusion criteria: heart failure NYHA class III/IV; stage III chronic renal insuffi-
ciency; severe peripheral arterial disease; acute thrombophlebitis; neurological disorders
or arthrodeses of the lower limbs; recent anticoagulation; hemorrhagic diathesis; allergy
to heparins; or active malignant disease
Interventions Intervention group: LMWH, enoxaparin (40 mg daily, subcutaneously) and pneumatic
sequential compression
Control group: LMWH, enoxaparin (40mg daily, subcutaneously) and class-I graduated
compression stockings
Outcomes Symptomatic and asymptomatic DVT (on ultrasound)
Notes The calf cuffs were applied to both lower limbs directly after the operation in the recovery
room and the system was activated. The use of the IPC was continued until the tenth
postoperative day whenever the patient was in bed
Enoxaparin was started the evening before surgery and continued for 30 days
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details provided
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk A placebo device was not used
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Color duplex ultrasonography was per-
formed by an independent angiologist who
was unaware of the patients’ participation
in the study or of the method of prophy-
laxis, but only to confirm the findings of
compression ultrasonography, which was
not reported to be performed by a blinded
or not observer, hence unclear risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Eight patients who were randomized were
subsequently excluded (two from the
LMWH/IPC and six from the LMWH/
GCS group) for various reasons, but they
represent a small percentage of the total pa-
tient number, unlikely to change they re-
sults and conclusions whatever their out-
come might have been
Selective reporting (reporting bias) Low risk Thromboembolic (VTE) events were
stated in methodology to be the outcome
measures of the study and they were re-
ported as such
Other bias Low risk Baseline characteristics were comparable
Siragusa 1994
Methods Study design: randomized controlled trial
Method of randomization: unclear
Concealment of allocation: unclear
Exclusions: none
Losses to follow up: none
Intention-to-treat analysis: yes
Participants Country: Italy
Number of participants: 70
Age (mean, years): not provided
Sex: not provided
Inclusion criteria: elective hip replacement
Exclusion criteria: not provided
Interventions Intervention group: IPC + UFH
Control group: UFH
Outcomes DVT on venography
Notes No information on start and discontinuation of IPC or UFH
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details provided
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk A placebo device was not used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is unclear if the personnel performing di-
agnostic testing were aware of patient allo-
cation
Incomplete outcome data (attrition bias)
All outcomes
Low risk No exclusions orwithdrawalswere reported
Selective reporting (reporting bias) Low risk DVT was the only VTE event stated in
methodology and was reported
Other bias Unclear risk Insufficient details were provided to allow
a conclusion to be made
Song 2014
Methods Study design: randomized controlled trial
Method of randomization: computer-randomized treatment assignments
Concealment of allocation: sequential sealed envelopes
Exclusions: 15 patients did not have the planned ultrasound scan to detect DVT, al-
though the exact reason for exclusion from the final analysis was provided only for three
patients: one came down with heparin-induced thrombocytopenia, one withdrew in-
formed consent after surgery, and one underwent bypass surgery that led to noncurative
operation
Losses to follow up: none
Intention-to-treat analysis: yes
Participants Country: Korea
Number of participants: 220
Age (mean, years): 57.6
Sex: 68.2 % (150) of the patients were male
Inclusion criteria: gastric cancer patients with histologically proven adenocarcinoma
undergoing surgery
Exclusion criteria: history of PE or DVT in the previous 1 year; preoperative prolonged
immobilization or being wheelchair bound; diseases of bleeding tendency; major surgery
in the previous 6 months; cerebrovascular accident in the previous 3 months; uncon-
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trolled hypertension; congestive cardiac failure; renal or liver impairment; allergy to hep-
arin or heparin-induced thrombocytopenia; varicose veins or chronic venous insuffi-
ciency; previous chemotherapy; radiotherapy; anticoagulation therapy; transfusion; body
mass index (BMI) ≤ 18.5 kg/m2; pregnancy or plan to become pregnant
Interventions Intervention group: IPC combined with enoxaparin 40 mg OD
Control group: IPC
Outcomes DVT on duplex ultrasound but also clinically evident DVT and PE
Bleeding: major and minor, no specific bleeding definitions provided
Notes Interim analysis
The IPC was initiated preoperatively and continued until postoperative discharge
Enoxaparin started postoperatively but the exact time of start and discontinuation was
not provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-randomized treatment assign-
ments
Allocation concealment (selection bias) High risk Sequential sealed envelopes, but no state-
ment that these were opaque
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo injection was given
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is unclear if the personnel performing di-
agnostic testing were aware of patient allo-
cation
Incomplete outcome data (attrition bias)
All outcomes
High risk A relatively large number of patients in the
combined group did not have duplex ultra-
sonography
Selective reporting (reporting bias) Low risk DVT and PE were stated in methodology
to be the outcome measures of the study
and results were reported
Other bias Low risk Baseline characteristics were comparable
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Methods Study design: randomized controlled trial
Method of randomization and concealment of allocation: unclear
Exclusions: none
Losses to follow up: none
Intention-to-treat analysis: yes
Participants Country: USA
Number of participants: 75
Age (mean, years): 67.4
Sex: not reported
Inclusion criteria: patients undergoing elective uncemented hip arthroplasty
Exclusion criteria: not provided
Interventions Heparin/aspirin versus intermittent foot compression versus combined heparin/aspirin
and intermittent foot compression
Outcomes Asymptomatic DVT, symptomatic DVT, any DVT, PE
Notes The pumps were started in the recovery room immediately after surgery and used until
the end of the study, with the exact time not specified
Heparin was started 8 hours before the operation and after 3 days of use it was replaced
with 325 mg aspirin twice daily for an undefined duration
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details provided
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo for compression, heparin and
aspirin
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All duplex results and venograms were read
by one of the authors who was blinded to
the prophylactic modality used
Incomplete outcome data (attrition bias)
All outcomes
Low risk No patients were lost to follow-up
Selective reporting (reporting bias) Low risk DVT was stated in methodology to be the
outcome measure of the study and results
were reported
Other bias Low risk Baseline characteristics were comparable
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Tsutsumi 2012
Methods Study design: controlled clinical trial
Method of randomization: none
Concealment of allocation: not reported
Exclusions: none
Losses to follow up: none
Intention-to-treat analysis: yes
Participants Country: Japan
Number of participants: 137
Age (mean, years): 66.1 (calculated)
Sex: 83 men, 54 women
Inclusion criteria: patients with colorectal cancer undergoing elective resection surgery
under general anesthesia, regardless of tumor stage
Exclusion criteria: clinical signs of DVT, active bleeding, active GI ulceration, hemor-
rhagic stroke, contraindication for anticoagulation, indwelling epidural catheter, renal
failure and inability to receive intermittent pneumatic compression
Interventions Intervention group: IPC (stopped 24 hours after surgery) combined with fondaparinux
(subcutaneous injections of fondaparinux at 2.5 mg OD)
Control group: IPC (stopped 24 hours after surgery)
Outcomes Clinically evident DVT and PE
Bleeding: major bleeding was defined as bleeding that was fatal, retroperitoneal, intracra-
nial, involving any other critical organ, led to intervention being discontinued, or was
associated with a need for transfusion of more than 3 units of packed red blood cell.
Other types of bleeding was included and defined as bleeding that did not fulfil the
criteria for major bleeding
Notes IPC was used for 24 hours after surgery, but no information on when it was started
Fondaparinux was started 24 hours after surgery and was continued until days 5-7
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk The type of the study (CCT) makes it high
risk for selection bias
Allocation concealment (selection bias) High risk The type of the study (CCT) makes it high
risk for selection bias
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo for fondaparinux
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is unclear if the personnel performing di-
agnostic testing were aware of patient allo-
cation
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Incomplete outcome data (attrition bias)
All outcomes
Low risk All enrolled patients had results reported
Selective reporting (reporting bias) Low risk Thromboembolic events (DVT and PE)
were stated in methodology to be the out-
come measures of the study and they were
reported as such
Other bias Low risk Baseline characteristics were comparable
Turpie 2007
Methods Study design: randomized, double-blind, placebo-controlled, superiority trial
Method of randomization: centralized computer-generated schedule (1:1 randomization
in blocks of four and stratified by centre)
Concealment of allocation: yes
Exclusions post randomization: 24
Losses to follow up: none
Intention-to-treat analysis: no
Participants Country: USA
Number of participants: 1309 randomized, 1285 randomized and treated
Age: median age 59 and 60 years in the control and treatment groups, respectively
Sex: male 635; female 650
Inclusion criteria: abdominal surgery expected to last longer than 45 min in patients
aged over 40 years; or patients weighing over 50 kg
Exclusion criteria: vascular surgery with evidence of leg ischemia caused by peripheral
vascular disease; unable to receive intermittent pneumatic compression or elastic stock-
ings; pregnant women and women of childbearing age not using effective contracep-
tion; life-expectancy < 6 months; clinical signs of DVT and/or history of venous throm-
boembolism within the previous 3 months; active bleeding; documented congenital or
acquired bleeding disorder; active ulcerative gastrointestinal disease (unless it was the
reason for the present surgery); hemorrhagic stroke or surgery on the brain, spine or
eyes within the previous 3 months; bacterial endocarditis or other contraindications for
anticoagulant therapy; planned indwelling intrathecal or epidural catheter for more than
6 hours after surgical closure; unusual difficulty in achieving epidural or spinal anes-
thesia; known hypersensitivity to fondaparinux or iodinated contrast medium; current
addictive disorders; serum creatinine concentration above 2.0 mg/dL in a well-hydrated
patient; platelet count below 100 000 mm; or patients requiring anticoagulant therapy
or other pharmacologic prophylaxis besides intermittent pneumatic compression
Interventions Intervention group: fondaparinux and intermittent pneumatic compression
Control group: intermittent pneumatic compression
Outcomes Venous thromboembolism (defined as DVT detected by mandatory screening and/or
documented symptomatic DVT or PE, or both) and individual components up to day
10. Symptomatic venous thromboembolism up to day 10 and day 32
Major bleeding (defined as bleeding that was fatal, retroperitoneal, intracranial, or in-
47Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism
(Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Turpie 2007 (Continued)
volved any other critical organ, led to intervention being discontinued, or was associated
with a bleeding index of 2.0 or more) detected during the treatment period
Death during the treatment period and up to day 32
Notes Study medications were packaged in boxes of identical appearance
Of the 1309 randomized patients, 842 (64.3%) had an evaluable venogram performed
and were included in the primary efficacy analysis
Major bleeding occurred in 10 patients (1.6%) and 1 patient (0.2%) of the intervention
and control groups, respectively (P = 0.006)
During the on-study-drug period of 5-9 days, all patients were to receive venous throm-
boembolism prophylaxis with intermittent pneumatic compression using any type of
device, except a foot pump, for a duration left to the investigator’s discretion. The first
injection of fondaparinux or placebo was scheduled 6-8 h after surgical closure, provided
that hemostasis was achieved. The duration of the on-study-drug period was 5-9 days. If
the patient was discharged from hospital before completing the on-study-drug period, a
visiting nurse administered the remaining trial injections
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralized computer-generated sched-
ule randomization (1:1 randomization in
blocks of four and stratified by centre)
Allocation concealment (selection bias) Low risk Centralized computer-generated schedule
randomization
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Use of placebo injections
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Reports double-blind (use of placebo in-
jections) but it is unclear if the personnel
performing diagnostic testing were aware
of patient allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk A large number of exclusions in both trial
arms, around 35% of the total number
of participants, mainly because of lack of
mandatory or interpretable venography
Selective reporting (reporting bias) Low risk DVTandPEwere the primary efficacy out-
comes and they were reported in the results
Other bias Low risk Demographic variables and risk factors at
baseline, type of anesthesia, and type and
duration of surgery were similar in the
two groups among both randomized and
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treated patients (Tables 1 and2) and among
patients analysed for primary efficacy
Westrich 2005
Methods Study design: controlled clinical trial
Method of randomization: none
Concealment of allocation:: none
Exclusions: none
Losses to follow up: none
Intention-to-treat analysis: yes
Participants Country: USA
Number of participants: 200
Age (mean, years): 81.3
Sex: male 42; female 158
Inclusion criteria: patients older than 60 years who sustained a fragility fracture to the hip;
and an ability and willingness to comply with the mechanical and chemical prophylaxis
protocol
Exclusion criteria: patients younger than 60 years; history of severe allergy to aspirin or
warfarin; refusal to use the pneumatic compression device; multiple trauma injuries; or
patients with a hip fracture that did not require surgical treatment
Interventions Intervention group: pneumatic sequential compression and warfarin
Control group: pneumatic sequential compression and aspirin
Outcomes DVT on ultrasound of the ipsilateral lower external iliac, common femoral, superficial
femoral, deep femoral, and popliteal veins
Bleeding: all participants assessed for postoperative bleeding, no specific bleeding defi-
nition provided
Notes No symptomatic VTE was observed
Three patients on warfarin developed bleeding complications
The IPC device was applied over the duration of the patient’s preoperative and postop-
erative stay until the time of discharge. Patients sent to a rehabilitation center were told
to continue using the IPC until their final discharge home. Warfarin or aspirin started
on the night before surgery but no duration of use was provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk The type of the study (CCT) makes it high
risk for selection bias
Allocation concealment (selection bias) High risk The type of the study (CCT) makes it high
risk for selection bias
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not a double-blind study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is unclear if the personnel performing di-
agnostic testing were aware of patient allo-
cation
Incomplete outcome data (attrition bias)
All outcomes
Low risk No exclusions/participants lost to follow-
up
Selective reporting (reporting bias) Low risk DVT and PE were the main study out-
comes and they were reported in the results
Other bias Unclear risk Insufficient details were provided to allow
a conclusion to be made
Westrich 2006
Methods Study design: randomized controlled trial
Method of randomization: not reported
Concealment of allocation: not reported
Exclusions post randomization: 11
Losses to follow up: 73
Intention-to-treat analysis: no
Participants Country: USA
Number of participants: 275
Age (mean, years): 69
Sex: male 99; female 176
Inclusion criteria: unilateral TKA
Exclusion criteria: allergies to aspirin; congenital or acquired bleeding disorders; active
ulcerative or angiodysplastic gastrointestinal disease; multiple myeloma or other para-
proteinemias; pheochromocytoma; hyperthyroidism; impaired renal function; known
hepatic disease; past medical history of stroke; recent brain, spinal, or ophthalmologic
surgery; hypersensitivity to enoxaparin; cardiac complications; severe peripheral vascular
diseases; chronic heart failure; severe varicose veins; history of DVT and/or PE
Interventions Intervention group: pneumatic sequential compression and enoxaparin
Control group: pneumatic sequential compression and aspirin
Outcomes DVT on ultrasound before discharge on postoperative days 3 to 5, and 4 to 6 weeks after
surgery
Notes Bleeding complications were documented, no specific bleeding definitions provided
Upon their arrival in the recovery room, the patients received a VenaFlow calf compres-
sion device that was placed on both of their lower extremities. The compression device
was used during each patient’s entire hospital stay
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Enoxaparin was initiated 2 hours after epidural catheter removal (approx. 48 hours
postoperatively). Patients received 30 mg of enoxaparin twice daily until their hospital
discharge; upon discharge, their dosage was changed to 40 mg once daily for 3 weeks.
Aspirin started on the night of their surgery in the recovery room and was continued for
4 weeks postoperatively
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details provided
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not a blinded trial
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is unclear if the personnel performing di-
agnostic testing were aware of patient allo-
cation
Incomplete outcome data (attrition bias)
All outcomes
High risk A large number of patients were lost to fol-
low-up, likely to affect outcome results
Selective reporting (reporting bias) Low risk DVTwas the main study outcome and was
reported in the results
Other bias Low risk Baseline characteristics were comparable
Windisch 2011
Methods Study design: randomized controlled trial
Method of randomization: not provided
Concealment of allocation: not provided
Exclusions: none
Losses to follow up: none
Intention-to-treat analysis: yes
Participants Country: Germany
Number of participants: 80
Age (mean, years): 68.5 (calculated)
Sex: not provided
Inclusion criteria: patients undergoing total knee replacement (primary diagnosis of knee
“arthritis”)
Exclusion criteria: patients aged younger than 60 years, body mass index (BMI) > 40 or <
25, existing acute DVT, thrombophlebitic varicosis (stages II-IV acc. Marshall), venous
51Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism
(Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Windisch 2011 (Continued)
insufficiency (stages 2-3 according to Widmer)
Interventions Intervention group: IPC (foot pump) combined with enoxaparin (40mgOD, beginning
24 hours prior to the operation)
Control group: enoxaparin (40 mg OD, beginning 24 hours prior to the operation)
Outcomes DVT on duplex ultrasonography, but also clinically evident DVT and PE
Notes Reports none of the participants needed to be operated upon for hemarthrosis, no other
details regarding bleeding were provided
The AVI system was attached in the recovery room to both feet of the participants only
shortly after completion of the operation; patients were free to discontinue its use at will
Enoxaparin was started 24 hours before surgery, duration was not provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details provided
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk A placebo device was not used
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Sonographers were unaware of treatment
allocations
Incomplete outcome data (attrition bias)
All outcomes
Low risk No exclusions/patients lost to follow-up
Selective reporting (reporting bias) Low risk DVT and PE were VTE events stated in
methodology and were reported
Other bias Low risk There were no baseline imbalances
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Woolson 1991
Methods Study design: randomized controlled trial
Method of randomization: sealed envelopes
Concealment of allocation: sealed envelopes
Exclusions post randomization: none
Losses to follow up: none
Intention-to-treat analysis: yes
Participants Country: USA
Number of participants: 196 patients who had 217 procedures
Age (mean, years): 65
Sex: male 95 procedures; female 122 procedures
Inclusion criteria: primary or revision THA
Exclusion criteria: allergy to aspirin or warfarin; recent peptic ulcer or other bleeding
diathesis; receiving any drug that affects platelet function within two weeks before the
operation; or patients expected to remain in bed for more than four days after the
operation
Interventions Intervention group: pneumatic sequential compression, thigh-high graduated elastic
compression stockings, and warfarin (one group); or pneumatic sequential compression,
thigh-high graduated elastic compression stockings, and aspirin (second group)
Control group: pneumatic sequential compression and thigh-high graduated elastic com-
pression stockings
Outcomes Proximal DVT on venography, B-mode ultrasonography, or both, on discharge
Symptomatic DVT or PE, objectively diagnosed
Notes Warfarin dose was 7.5 or 10 mg orally on the evening before the operation, then titrated
to maintain the prothrombin time at 1.2 to 1.3 times the control value. Aspirin started
the evening before surgery and continued at a dose of 650 mg twice daily. For both
agents duration of use was not reported
IPC was started in the operating theater, as soon as the patient was draped and used
discharge
Follow up was at least 3 months for all patients
Bleeding: one patient in each of the three groups had a wound hematoma, that required
evacuation in the two intervention group patients but not in the control group. No
specific definition of bleeding provided
No complications related to the use of the elastic stockings or pneumatic compression
were reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Use of sealed envelope method
Allocation concealment (selection bias) Unclear risk Does not mention if the sealed envelopes
were sequentially numbered and opaque
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Woolson 1991 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not a blinded trial
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is unclear if the personnel performing di-
agnostic testing were aware of patient allo-
cation
Incomplete outcome data (attrition bias)
All outcomes
Low risk No patients were lost to follow-up
Selective reporting (reporting bias) Low risk DVTwas the main study outcome and was
reported in the results
Other bias Low risk There were no baseline imbalances
Yokote 2011
Methods Study design: randomized controlled trial
Method of randomization: not provided
Concealment of allocation: not provided
Exclusions: none
Losses to follow up: 3 patients withdrawn after randomization
Intention-to-treat analysis: yes
Participants Country: Japan
Number of participants: 255
Age (mean, years): 63.3 (calculated)
Sex: 204 females and 46 males
Inclusion criteria: elective primary unilateral total hip replacement
Exclusion criteria: bilateral and revision procedures, patients who were less than 20 years
of age, long-term anticoagulation treatment such as unfractionated heparin, LMWH,
vitamin K antagonists, antiplatelet agents for pre-existing cardiac or cerebrovascular
disease, a history of VTE, a coagulation disorder including antiphospholipid syndrome,
the presence of a solid malignant tumor or a peptic ulcer, and major surgery in the
preceding three months. Caucasian patients were also excluded
Interventions Intervention group:
1. Enoxaparin (20 mg BID) + IPC
2. Fondaparinux (2.5 mg OD) + IPC
Control group: placebo + IPC
Outcomes DVT on duplex ultrasonography and also clinically evident DVT and PE
Any bleeding, both major or minor. Major bleeding: retro-peritoneal, intracranial or
intraocular, or if associated with either death, transfusion of more than two units of
packed red blood cells or whole blood (except autologous), a reduction in the level
of hemoglobin of > 2 g/dL, or a serious or life-threatening clinical event requiring
medical intervention. Suspected intra-abdominal or intracranial bleeding was confirmed
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Yokote 2011 (Continued)
by ultrasonography, CT or MRI Minor bleeding: epistaxis lasting for more than five
minutes or requiring intervention, ecchymosis or hematoma with a maximum size of >
5 cm, hematuria not associated with trauma from the urinary catheter, gastrointestinal
hemorrhage not related to intubation or the passage of a nasogastric tube, a wound
hematoma or hemorrhagic wound complications not associated with major hemorrhage
or subconjunctival hemorrhage, requiring cessation of medication
Notes The pneumatic devices were initiated in the operating theater (before surgery for the
contralateral leg and just after surgery for the operated leg) and removed on the “second
post-operative day when the day of surgery was defined as post-operative day 1”
Pharmacological prophylaxis was started postoperatively
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details provided
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Use of placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Scans were read by experiences radiologist
blinded to randomisation
Incomplete outcome data (attrition bias)
All outcomes
Low risk A small percentage of exclusions (5/255,
2%)
Selective reporting (reporting bias) Low risk DVT and PE were the main study out-
comes and they were reported in the results
Other bias Low risk Baseline characteristics were comparable
BID: twice daily
DVT: deep vein thrombosis
IPC: intermittent pneumatic compression
IPG: impedence plethysmography
iu: international units
LMWH: low molecular weight heparin
mg: milligrams
NYHA: New York Hospital Association
OD: once daily
PE: pulmonary embolism
THA: total hip arthroplasty
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THR: total hip replacement
TKR: total knee replacement
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ailawadi 2001 Retrospective case-control study
Eskander 1997 Use of combined modalities was not concurrent in the intervention group
Frim 1992 Controlled before and after study
Gagner 2012 Registry study, non-randomized
Gelfer 2006 Pharmacological prophylaxis was not the same in the two study groups
Kamran 1998 Controlled before and after study
Kiudelis 2010 Investigation restricted to intraoperative period up to 10 min after extubation
Kumaran 2008 The control (single modality) group included patients who were allocated to heparin or pneumatic
compression
Lieberman 1994 Pharmacological prophylaxis consisted of aspirin, which has limited thromboprophylactic proper-
ties
Macdonald 2003 Pharmacological prophylaxis was not the same in the two study groups
Mehta 2010 Only aggregated VTE rates and not separate DVT and PE rates were provided and the authors did
not reply when individual data were requested
Nathan 2006 Prospective case-control study
Patel 2010 Retrospective study
Roberts 1975 Pneumatic compression was used only intraoperatively
Spinal cord injury investigators Pharmacological prophylaxis was not the same in the two study groups
Stannard 2006 Use of enoxaparin was not concurrent in the two study groups
Tsutsumi 2000 Controlled before and after study
Wan 2015 Retrospective study
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(Continued)
Westrich 1996 Pharmacological prophylaxis consisted of aspirin, which has limited thromboprophylactic proper-
ties
Whitworth 2011 Retrospective case-control study investigating preoperative anticoagulation in patients on postop-
erative low molecular-weight heparin and SCDs
Winemiller 1999 Retrospective case-control study
DVT: deep vein thrombosis
PE: pulmonary embolism
SCD: sequential compression device
VTE: venous thromboembolism
Characteristics of ongoing studies [ordered by study ID]
CHICTR-IPR-15007324
Trial name or title The mechanical and medical prevention of lower extremity deep venous thrombosis formation post gyneco-
logic pelvic surgery, a multiple center randomized case control study
Methods Randomized parallel controlled trial
Participants Women undergoing gynecologic pelvic surgery
Interventions GCS: graduated compression stockings; GCS + LMWH: graduated compression stockings + low molecular
weight heparin; GCS + IPC: graduated compression stockings + intermittent pneumatic compression; GCS
+ LMWH + IPC: graduated compression stockings + low molecular weight heparin + intermittent pneumatic
compression
Outcomes DVT on ultrasound of the leg veins (primary); hemoglobin; white blood cell count; hematocrit; platelets; PT;
APTT; Fbg; TT; D-Dimer; AT-III; t-PA; PAI; VIII factor; X factor; Protein c; Protein s; CTPA (all secondary)
Starting date November 2015
Contact information Cuiqin Sang, 22 South Sanlitun Road, Beijing, China
Notes Target sample size: GCS: 250; GCS + LMWH: 250; GCS + IPC: 250; GCS + LMWH + IPC: 250
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ISRCTN44653506 and NCT02040103
Trial name or title The PREVENT Trial: pneumatic compression for PREventing VENous Thromboembolism
Methods RCT in ICU patients already receiving anticoagulants
Participants No further information is provided
Interventions Patients were randomized to use IPC or not
Outcomes Incidence of proximal leg DVT up to 30 days (primary), PE up to 30 days (secondary), ICU and hospital
mortality (secondary)
Starting date December 2013
Contact information Dr Yaseen Arabi
Notes Trial completed, no longer recruiting
NCT00740987
Trial name or title Efficacy of the association mechanical prophylaxis plus anticoagulant prophylaxis on venous thromboem-
bolism incidence in intensive care unit (ICU) (CIREA2)
Methods RCT in ICU patients without high risk of bleeding
Participants 621 ICU patients
Interventions Patients were randomized to use IPC or not
Outcomes Primary outcome measures: combined criterion evaluated at day 6 ± 2 days after randomization: symptomatic
venous thromboembolic event, non-fatal, objectively confirmed; death related to PE; asymptomatic DVT of
the lower limbs detected by CUS on day 6 (time frame: 6 ± 2 days)
Secondary outcome measures: symptomatic thromboembolic events occurred between day 6 and day 90;
total mortality evaluated at 1 month and 3 months (time frame: 6 days to 3 months)
Starting date October 2007
Contact information Karine Lacut, MD. CHU Brest France, Univ Brest, EA 3878
Notes Study completed in January 2015, with no results being presented or published at the time of writing this
review
APTT: activated partial thromboplastin time
CTPA: computed tomography pulmonary angiogram
CUS: colour ultrasound
DVT: deep vein thrombosis
Fbg: fibrinogen
GCS: graduated compression stockings
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ICU: intensive care unit
IPC: intermittent pneumatic compression
LMWH: low molecular weight heparin
PAI: plasminogen activator inhibitor
PE: pulmonary embolism
PT: prothrombin time
RCT: randomized controlled trial
TT: thrombin time
t-PA: tissue plasminogen activator
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D A T A A N D A N A L Y S E S
Comparison 1. IPC plus pharmacological prophylaxis versus IPC alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of PE 12 3017 Odds Ratio (M-H, Fixed, 95% CI) 0.49 [0.18, 1.34]
2 Incidence of DVT 11 2934 Odds Ratio (M-H, Fixed, 95% CI) 0.52 [0.33, 0.82]
3 Incidence of symptomatic DVT 6 2526 Odds Ratio (M-H, Fixed, 95% CI) 0.49 [0.16, 1.47]
4 Incidence of DVT by foot IPC
or other IPC
11 2934 Odds Ratio (M-H, Fixed, 95% CI) 0.52 [0.33, 0.82]
4.1 foot IPC 1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 other IPC 10 2884 Odds Ratio (M-H, Fixed, 95% CI) 0.52 [0.33, 0.82]
5 Incidence of bleeding 7 2155 Odds Ratio (M-H, Fixed, 95% CI) 5.04 [2.36, 10.77]
6 Incidence of major bleeding 7 2155 Odds Ratio (M-H, Fixed, 95% CI) 6.81 [1.99, 23.28]
Comparison 2. IPC plus pharmacological prophylaxis versus pharmacological prophylaxis alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of PE 10 3544 Odds Ratio (M-H, Fixed, 95% CI) 0.39 [0.23, 0.64]
2 Incidence of DVT 11 2866 Odds Ratio (M-H, Random, 95% CI) 0.42 [0.18, 1.03]
3 Incidence of symptomatic DVT 5 2312 Odds Ratio (M-H, Fixed, 95% CI) 1.02 [0.29, 3.54]
4 Incidence of DVT by foot IPC
or other IPC
11 2866 Odds Ratio (M-H, Random, 95% CI) 0.42 [0.18, 1.03]
4.1 foot IPC 4 324 Odds Ratio (M-H, Random, 95% CI) 0.40 [0.05, 3.47]
4.2 other IPC 7 2542 Odds Ratio (M-H, Random, 95% CI) 0.39 [0.16, 0.96]
5 Incidence of bleeding 3 244 Odds Ratio (M-H, Fixed, 95% CI) 0.80 [0.30, 2.14]
6 Incidence of major bleeding 3 244 Odds Ratio (M-H, Fixed, 95% CI) 1.21 [0.35, 4.18]
Comparison 3. IPC plus pharmacological prophylaxis versus IPC plus aspirin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of PE 3 605 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.03, 3.19]
2 Incidence of DVT 3 605 Odds Ratio (M-H, Fixed, 95% CI) 0.83 [0.48, 1.42]
3 Incidence of symptomatic DVT 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Incidence of bleeding 3 616 Odds Ratio (M-H, Fixed, 95% CI) 1.23 [0.27, 5.53]
5 Incidence of major bleeding 3 616 Odds Ratio (M-H, Fixed, 95% CI) 0.80 [0.15, 4.17]
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Comparison 4. IPC plus pharmacological prophylaxis versus IPC alone - subgroups
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of PE 12 3017 Odds Ratio (M-H, Fixed, 95% CI) 0.49 [0.18, 1.34]
1.1 Orthopedic patients 3 445 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Non-orthopedic patients 9 2572 Odds Ratio (M-H, Fixed, 95% CI) 0.49 [0.18, 1.34]
2 Incidence of DVT 11 2934 Odds Ratio (M-H, Fixed, 95% CI) 0.52 [0.33, 0.82]
2.1 Orthopedic patients 3 445 Odds Ratio (M-H, Fixed, 95% CI) 0.80 [0.38, 1.69]
2.2 Non-orthopedic patients 8 2489 Odds Ratio (M-H, Fixed, 95% CI) 0.41 [0.23, 0.73]
Comparison 5. IPC plus pharmacological prophylaxis versus pharmacological prophylaxis alone - subgroups
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of PE 10 3544 Odds Ratio (M-H, Fixed, 95% CI) 0.39 [0.23, 0.64]
1.1 Orthopedic patients 6 732 Odds Ratio (M-H, Fixed, 95% CI) 0.58 [0.08, 4.49]
1.2 Non-orthopedic patients 4 2812 Odds Ratio (M-H, Fixed, 95% CI) 0.38 [0.22, 0.63]
2 Incidence of DVT 11 2866 Odds Ratio (M-H, Random, 95% CI) 0.42 [0.18, 1.03]
2.1 Orthopedic patients 8 2605 Odds Ratio (M-H, Random, 95% CI) 0.32 [0.12, 0.86]
2.2 Non-orthopedic patients 3 261 Odds Ratio (M-H, Random, 95% CI) 1.77 [0.30, 10.58]
Comparison 6. IPC plus pharmacological prophylaxis versus IPC alone - RCTs only
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of PE 7 2023 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.09, 2.76]
2 Incidence of DVT 7 2008 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.35, 0.90]
Comparison 7. IPC plus pharmacological prophylaxis versus pharmacological prophylaxis alone - RCTs only
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of PE 8 3285 Risk Ratio (M-H, Fixed, 95% CI) 0.40 [0.24, 0.65]
2 Incidence of DVT 9 2607 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.19, 1.26]
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Comparison 8. IPC plus pharmacological prophylaxis versus IPC plus aspirin - RCTs only
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of PE 2 405 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.03, 3.17]
2 Incidence of DVT 2 405 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.50, 1.33]
F E E D B A C K
Anticoagulant feedback, 14 February 2011
Summary
Feedback received on this review, and other reviews and protocols on anticoagulants, is available on the Cochrane Editorial Unit website
at http://www.editorial-unit.cochrane.org/anticoagulants-feedback.
WH A T ’ S N E W
Date Event Description
3 May 2016 New citation required but conclusions have not changed Search updated. Eleven new studies included, nine new
studies excluded and three ongoing studies identified.New
author added. Cochrane Risk of bias assessments and
’Summary of findings’ table added. Text amended to re-
flect current Cochrane standards. No change to conclu-
sions
3 May 2016 New search has been performed Search updated. Eleven new studies included, nine new
studies excluded and three ongoing studies identified
H I S T O R Y
Date Event Description
14 February 2011 Amended Link to anticoagulant feedback added.
16 June 2008 Amended Converted to new review format.
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C O N T R I B U T I O N S O F A U T H O R S
SKK: selected trials, assessed trial quality, and extracted data
JC: arbitrated disagreements
GG: selected trials, assessed trial quality, and extracted data
AN: contributed to the text of the review
GS: contributed to the text of the review
DR: contributed to the text of the review
IN: selected trials, assessed trial quality, and extracted data
D E C L A R A T I O N S O F I N T E R E S T
SKK: has declared that he has received consulting fees fromCovidien (small lecture fees from companies now taken over and incorporated
by Covidien), Sanofi (research funding and travel grants), LEO (research funding), Bayer (research funding and travel grants), all
unrelated to the subject of this review
JC: has declared that he received consultancy fees from Janssen Research andDevelopment (meeting to discuss protocol), Pfizer (meeting
to discuss bleeding issues) and BMS Medtronics (advisory board meeting consultant). He received payment for lectures from Sanofi
Poland (lecture to Vascular surgical society) and CHEST enterprises (lectures to Pharma group concerning guidelines). These were
unrelated to the subject of this review
GG: none known
AN: none known
GS: none known
DR: none known
IN: none known
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The outcomes incidence of bleeding, incidence of major bleeding, and fatal bleeding are important adverse events of pharmacological
prophylaxis and have therefore been added to the review.
The outcome fatal PE has been added to the review for completeness.
The method of evaluating study quality has changed since the protocol was published; we used the Cochrane ’Risk of bias’ tool (
Higgins 2011). We have also added ’Summary of findings’ tables.
Because risk stratification of study participants was not provided nor based on modern or any methodology, all types of participants
were included and not only those considered as being at high risk of developing VTE; however many studies included in this review
included high risk patients such as those undergoing orthopedic surgery.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Intermittent PneumaticCompressionDevices; Anticoagulants [∗ therapeutic use]; CombinedModalityTherapy [methods];Controlled
Clinical Trials as Topic; Leg [blood supply]; Pulmonary Embolism [∗prevention & control]; Venous Thromboembolism [prevention
& control]; Venous Thrombosis [∗prevention & control]
MeSH check words
Humans
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